<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001737.pub3" GROUP_ID="WOUNDS" ID="497799072109545970" MERGED_FROM="" MODIFIED="2012-12-05 08:08:12 +0000" MODIFIED_BY="Sally Bell-Syer" REVIEW_NO="007" REVMAN_SUB_VERSION="5.2.0 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2012-12-05 08:08:12 +0000" MODIFIED_BY="Sally Bell-Syer">
<TITLE>Skin grafting for venous leg ulcers</TITLE>
<CONTACT MODIFIED="2012-12-05 08:08:12 +0000" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="16754" ROLE="AUTHOR"><FIRST_NAME>June</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Jones</LAST_NAME><EMAIL_1>jonj@btinternet.com</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>82 Bibby Road</ADDRESS_1><ADDRESS_2>Churchtown</ADDRESS_2><CITY>Southport</CITY><ZIP>PR9 7PS</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-12-05 08:08:12 +0000" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="16754" ROLE="AUTHOR"><FIRST_NAME>June</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Jones</LAST_NAME><EMAIL_1>jonj@btinternet.com</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>82 Bibby Road</ADDRESS_1><ADDRESS_2>Churchtown</ADDRESS_2><CITY>Southport</CITY><ZIP>PR9 7PS</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="15777" ROLE="AUTHOR"><FIRST_NAME>E Andrea</FIRST_NAME><LAST_NAME>Nelson</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>e.a.nelson@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Healthcare</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>Baines Wing</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS2 9UT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 343 1373</PHONE_1><FAX_1>+44 113 343 7560</FAX_1></ADDRESS></PERSON><PERSON ID="46518933064487772801110503131338" ROLE="AUTHOR"><FIRST_NAME>Aws</FIRST_NAME><LAST_NAME>Al-Hity</LAST_NAME><EMAIL_1>alhitya@googlemail.com</EMAIL_1><MOBILE_PHONE>07794623221</MOBILE_PHONE><ADDRESS><ORGANISATION/><ADDRESS_1>5 Titania Close</ADDRESS_1><CITY>Bingley</CITY><ZIP>BD16 1WE</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-11-30 09:46:09 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="6" MONTH="1" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-07 13:42:20 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-07 13:37:41 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-11-07 13:42:20 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Fourth update, new search, one new trial included (<LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>); one trial previously included now excluded (<LINK REF="STD-Mol-1991" TYPE="STUDY">Mol 1991</LINK>); one study is awaiting assessment (<LINK REF="STD-Wille-2011" TYPE="STUDY">Wille 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-07-07 11:28:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Third update, two new trials added, no change to conclusions</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
<P>For this second update, new searches were carried out in February 2006. Twenty-six potentially relevant citations were identified, of these six studies (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>) were included in the review. Two studies (<LINK REF="STD-Calonge-1993" TYPE="STUDY">Calonge 1993</LINK>; <LINK REF="STD-Pojda-1994" TYPE="STUDY">Pojda 1994</LINK>) previously awaiting assessment have now been excluded.<BR/>The review authors' conclusions remain unchanged.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>For the first update, new searches were carried out in June 2004. Three new studies were identified. Of these, two studies (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>) were included in the review and one study (<LINK REF="STD-Halter-2003" TYPE="STUDY">Halter 2003</LINK>) was excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Health Sciences, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>School of Healthcare, University of Leeds, Leeds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Health Technology Assessment Programme, England</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-12-05 08:07:39 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-10-27 06:13:17 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-29 12:35:36 +0000" MODIFIED_BY="[Empty name]">Skin grafts to improve leg ulcer healing</TITLE>
<SUMMARY_BODY MODIFIED="2009-10-27 06:13:17 +0000" MODIFIED_BY="[Empty name]">
<P>Approximately 1% of people in industrialised countries have a leg ulcer at some time, mainly caused by poor blood flow back from the legs towards the heart. Skin grafts, either using the patient's own skin, artificial skin or donor skin/cells, have been evaluated to see whether they improve the healing of ulcers. The review of trials found evidence that tissue-engineered skin composed of two layers increases the chance of healing. There was not enough evidence to recommend any other type of graft, and further research is required.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-11-07 13:59:52 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-11-01 15:59:10 +0000" MODIFIED_BY="[Empty name]">
<P>Venous leg ulceration is a recurrent, chronic, disabling condition. It affects up to one in 100 people at some time in their lives. Standard treatments are simple dressings and compression bandages or stockings. Sometimes, despite treatment, ulcers remain open for months or years. Sometimes skin grafts are used to stimulate healing. These may be taken, or grown into a dressing, from the patient's own uninjured skin (autografts), or applied as a sheet of bioengineered skin grown from donor cells (allograft). Preserved skin from other animals, such as pigs, has also been used (xenografts).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effect of skin grafts for treating venous leg ulcers.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-11-07 13:59:52 +0000" MODIFIED_BY="[Empty name]">
<P>For this update we modified the search strategies and conducted searches of The Cochrane Wounds Group Specialised Register (searched 27 July 2012); The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2012, Issue 7); Ovid MEDLINE (2008 to July Week 3 2012); Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations, July 26, 2012); Ovid EMBASE (2008 to 2012 Week 29); and EBSCO CINAHL (2008 to 26 July 2012). We did not apply date or language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) of skin grafts in the treatment of venous leg ulcers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-19 13:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently undertook data extraction and assessment of study quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-01 15:59:21 +0000" MODIFIED_BY="[Empty name]">
<P>For this update of the review, we identified one new trial, bringing the total to 17 trials (1034 participants) - all of which were generally at moderate or high risk of bias. In 12 trials participants also received compression bandaging.</P>
<P>Eleven trials compared a graft with standard care in which no graft was used. Two of these trials (102 participants) compared a dressing with an autograft; three trials (80 participants) compared frozen allografts with dressings, and two trials (45 participants) compared fresh allografts with dressings. Two trials (345 participants) compared tissue-engineered skin (bilayer artificial skin) with a dressing. In two trials (97 participants) a single-layer dermal replacement was compared with standard care.</P>
<P>Six trials compared alternative skin grafting techniques. The first trial (92 participants) compared autografts with frozen allograft, a second (51 participants) compared a pinch graft (autograft) with porcine dermis (xenograft), the third (110 participants) compared growth-arrested human keratinocytes and fibroblasts with placebo, the fourth (10 participants) compared an autograft delivered on porcine pads with an autograft delivered on porcine gelatin microbeads, the fifth trial (92 participants) compared a meshed graft with a cultured keratinocyte autograft, and the sixth trial (50 participants) compared a frozen keratinocyte allograft with a lyophilised (freeze-dried) keratinocyte allografts.</P>
<P>Significantly more ulcers healed when treated with bilayer artificial skin than with dressings. There was insufficient evidence from the other trials to determine whether other types of skin grafting increased the healing of venous ulcers.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-10-27 06:12:33 +0000" MODIFIED_BY="[Empty name]">
<P>Bilayer artificial skin, used in conjunction with compression bandaging, increases venous ulcer healing compared with a simple dressing plus compression. Further research is needed to assess whether other forms of skin grafts increase ulcer healing.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-30 11:05:10 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]">
<P>The prevalence of active leg ulceration in the UK and Australia has been estimated at 1.5/1000 (<LINK REF="REF-Baker-1992" TYPE="REFERENCE">Baker 1992</LINK>; <LINK REF="REF-Callam-1985" TYPE="REFERENCE">Callam 1985</LINK>; <LINK REF="REF-Lees-1992" TYPE="REFERENCE">Lees 1992</LINK>) and it is estimated that one in 100 people will suffer from leg ulcers at some time in their lives. Prevalence increases with age and is higher among women. Typically, leg ulceration is a chronic, recurring condition; indeed 45% of participants in a Scottish study reported episodes of ulceration over more than 10 years (<LINK REF="REF-Callam-1989" TYPE="REFERENCE">Callam 1989</LINK>). There is a considerable cost both to the patient (<LINK REF="REF-Charles-1995" TYPE="REFERENCE">Charles 1995</LINK>) and to the health service (<LINK REF="REF-Bosanquet-1992" TYPE="REFERENCE">Bosanquet 1992</LINK>). Most leg ulcers are associated with venous disease. Venous insufficiency has been shown to be associated with increased hydrostatic pressure in the veins of the legs; application of externally applied compression to reverse this is largely successful in healing venous leg ulcers. Standard therapy involves the use of dressings to protect the wound bed from trauma and absorb exudate, and compression bandages to treat the venous insufficiency and promote healing.</P>
<P>Whilst compression therapy undoubtedly addresses the underlying pathology, it may be insufficient to heal all ulcers caused by venous disease in instances where the patient's own, intrinsic, wound-healing mechanism is inadequate. Additional treatments such as venous surgery to correct the high venous pressure, drug therapy to improve blood flow, or skin grafting to promote healing and close the wound may be used in this group of patients. However, it needs to be established whether skin grafts have an effect on the rate of healing and other outcomes.</P>
<P>A number of skin replacements and substitutes are available: these are generally classified as autografts (skin or cells taken from another site on the same patient); allografts (skin or cells taken from another person); and xenografts (skin or cells taken from one species to an unlike species; for example, from pig to human). These grafts may be applied in the form of layers of cells grown in the laboratory, pinches of skin, or dressings incorporating skin cells. The ulcer is usually debrided (cleaned) prior to application of the graft to remove dead tissue and allow the cells in the graft to make intimate contact with the ulcer bed and blood supply.</P>
<P>The types of skin grafts considered in this review include the following.<BR/>
</P>
<UL>
<LI>Autografts taken from the patient during a minor surgical procedure (pinch grafts, split-thickness mesh grafts, full-thickness skin grafts) or after growing the patients' cells (including keratinocytes from hair follicles) to form a thin film in the laboratory (cultured keratinocyte autograft, or a cultured epidermal autograft).</LI>
<LI>Allografts (allogeneic) taken from other human sources (cultured keratinocytes, cultured epidermal fibroblasts), grown in the laboratory and kept ready for use when necessary.</LI>
<LI>Xenografts, usually taken from pigs, as their skin has a similar structure to human skin.</LI>
<LI>Artificial skin, also called tissue-engineered skin, bioengineered skin or human skin equivalents (such as Apligraf (Novartis), Dermagraft (Smith &amp; Nephew) or Orcel (Ortec International) (all trademarks)). These products all feature a matrix into which cells important for skin repair are 'seeded'. There are both single and bilayer products. The bilayer products, such as Apligraf (Novartis) and Orcel (Ortec International) contain epidermal as well as dermal skin components. For example, Apligraf (Novartis) consists of Type 1 bovine collagen and human allogeneic cells (keratinocytes and fibroblasts) with an epidermis (upper layer) of cornified differentiated keratinocytes and a lower, dermal matrix of a collagen lattice containing viable fibroblasts. Dermagraft (Smith and Nephew) contains only a lower, dermal component. The most serious concern with allogeneic skin is the possibility of transmission of infection, particularly of the human immunodeficiency virus (HIV) or hepatitis. Even with rigorous screening it is still possible that skin could be harvested from an HIV-infected but seronegative donor (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>).</LI>
</UL>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-11-06 12:25:59 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of skin grafting on the healing of venous ulcers. </P>
<P>Specific questions addressed by the review were:</P>
<OL>
<LI>Does the application of a skin graft aid venous ulcer healing, when compared with standard care?</LI>
<LI>What is the comparative benefit of one type of skin graft compared with another?</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2012-08-01 08:58:16 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-01 15:59:34 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-11-01 15:59:32 +0000" MODIFIED_BY="[Empty name]">
<P>We included trials if the allocation of participants was described as randomised. We included cross-over trials only if the outcomes at the point of cross-over were given, as data after this point were not based on comparable baseline groups. There was no restriction on study reports based on language or publication status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-10-27 06:21:03 +0000" MODIFIED_BY="[Empty name]">
<P>We included studies involving participants of any age, in any care setting, and with venous leg ulceration (which may also be described as stasis or varicose ulceration). As the method of diagnosis of venous ulceration varies between studies, we did not apply a standard definition. We included trials that included participants with arterial, mixed, neuropathic and diabetic ulcers <I>only</I> if the outcomes for those with venous ulcers were reported separately.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-09-19 19:47:07 +0100" MODIFIED_BY="[Empty name]">
<P>The primary intervention was skin grafts or skin replacements applied to venous leg ulcers.</P>
<P>We included studies which compared the following types of grafts with any other intervention:</P>
<OL>
<LI>pinch grafts (autografts);</LI>
<LI>split-thickness grafts (autografts);</LI>
<LI>full-thickness grafts (autografts and xenografts);</LI>
<LI>cultured keratinocytes/epidermal grafts (allografts and xenografts);</LI>
<LI>artificial skin (allografts).</LI>
</OL>
<P>We also considered studies that compared skin grafting with no other intervention, and comparisons between skin grafts.</P>
<P>We excluded studies that evaluated cell lysate products against dressings or each other as these do not retain cell or skin structure. We excluded studies of interventions to improve graft survival (e.g. dressing A compared with dressing B over newly-applied skin grafts), as this does not compare grafts against non-graft therapies or against other graft treatments, and therefore provides little information on the effectiveness of the graft itself.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-01 15:59:34 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-26 15:11:29 +0100" MODIFIED_BY="[Empty name]">
<P>In order to be included in the review, a trial had to report at least one of the primary outcomes: i.e. objective measures of healing such as relative or absolute rate of change in ulcer area; time to complete healing; or proportion of ulcers healed within the trial period.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-11-01 15:59:34 +0000" MODIFIED_BY="[Empty name]">
<P>Secondary outcomes included: costs; quality of life; pain; side effects; adverse events; withdrawals and acceptability of treatment.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-08-01 08:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>The search methods section for the third update of this review can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>For this fourth update we searched the following electronic databases:</P>
<UL>
<LI>The Cochrane Wounds Group Specialised Register (searched 27 July 2012);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2012, Issue 7);</LI>
<LI>Ovid MEDLINE (2008 to July Week 3 2012);</LI>
<LI>Ovid MEDLINE (In-Process &amp; Other Non-Indexed Citations, July 26, 2012);</LI>
<LI>Ovid EMBASE (2008 to 2012 Week 29);</LI>
<LI>EBSCO CINAHL (2008 to 26 July 2012).</LI>
</UL>
<P>We used the following search strategy in the Cochrane Central Register of Controlled Trials (CENTRAL):</P>
<P>#1 MeSH descriptor Leg Ulcer explode all trees<BR/>#2 (varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg NEXT ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*) or ((lower NEXT extremit*) NEAR/2 ulcer*) or (crural NEXT ulcer*) or &#8220;ulcus cruris&#8221;:ti,ab,kw<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Skin Transplantation explode all trees<BR/>#5 (skin NEXT graft*) or (pinch NEXT graft*):ti,ab,kw<BR/>#6 (split NEXT thickness) or (full NEXT thickness):ti,ab,kw<BR/>#7 allograft* or dermagraft* or apligraf*:ti,ab,kw<BR/>#8 tissue NEAR/2 engineer*:ti,ab,kw<BR/>#9 cultured NEAR/2 keratinocyte*:ti,ab,kw<BR/>#10 artificial NEXT skin:ti,ab,kw<BR/>#11 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 (#3 AND #11)</P>
<P>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> respectively. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We combined the EMBASE and CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<LINK REF="REF-SIGN-2011" TYPE="REFERENCE">SIGN 2011</LINK>). We applied no date or language restrictions.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-01 16:00:14 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-11-01 15:59:48 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed titles and abstracts of studies identified by the search strategy in terms of their relevance and design according to the selection criteria. We obtained (and translated if necessary) copies of all relevant and potentially relevant abstracts. We obtained full versions of articles if, from this initial assessment, they satisfied the inclusion criteria. Another review author repeated the processes of (a) identifying potentially relevant papers and (b) selecting papers based on the full text independently for verification. We resolved any disagreements by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-11-01 15:59:51 +0000" MODIFIED_BY="[Empty name]">
<P>The primary review author (JEJ) extracted details of eligible studies and summarised them using a data extraction sheet. The second review author (EAN) checked data extraction.</P>
<P>We extracted the following data for each study:</P>
<OL>
<LI>patient inclusion/exclusion criteria;</LI>
<LI>care setting;</LI>
<LI>key baseline variables by group, e.g. age, sex, baseline area of ulcer, duration of ulcer;</LI>
<LI>description of the interventions and numbers of participants randomised to each intervention;</LI>
<LI>follow-up period;</LI>
<LI>outcomes.</LI>
</OL>
<P>If studies were published more than once, we used all reports in order to extract the maximum amount of data describing the trial and participants.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-09-19 19:53:50 +0100" MODIFIED_BY="[Empty name]">
<P>For this review update two review authors independently assessed each included study using the Cochrane Collaboration tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This tool addresses six specific domains, namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other issues (e.g. extreme baseline imbalance). We assessed blinding and completeness of outcome data for each outcome separately. We completed a 'Risk of bias' table for each eligible study and discussed any disagreement to achieve a consensus. We presented an assessment of risk of bias using a 'Risk of bias' summary figure (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), which presents all of the judgements in a cross-tabulation of study by entry. This display of internal validity indicates the weight the reader may give the results of each study.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-11-01 15:59:56 +0000" MODIFIED_BY="[Empty name]">
<P>Where two or more studies undertook similar comparisons in comparable populations using similar outcome measures, we assessed heterogeneity using the Chi² test. Where clinical and methodological heterogeneity were absent, but there was statistical heterogeneity (defined as a P value less than 0.1), we applied a random-effects model; in the absence of clinical, methodological and statistical heterogeneity, we applied a fixed-effect model. In addition, we assessed heterogeneity between study results using the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This examines the percentage of total variation across studies due to heterogeneity rather than to chance. Values of I² over 75% indicate a high level of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-11-01 16:00:14 +0000" MODIFIED_BY="[Empty name]">
<P>For each trial, we calculated the risk ratio (RR) with 95% confidence intervals (CI) for all dichotomous variables. The risk ratio indicates the relative benefit of a therapy but not the actual benefit. The absolute risk reduction (ARR) equals the arithmetic difference in healing rates between the experimental and control groups. The ARR tells us how much the difference is due to the graft itself and its inverse is the number needed to treat to benefit (NNTB). Thus a healing rate of 30% with a control dressing increased to 50% with a skin graft translates into an ARR of 50 to 30 = 20%, or 0.2. The NNT is therefore 1/0.2, or five participants. In other words, five participants would need to receive a skin graft in order for one additional ulcer to be healed.</P>
<P>When study reports failed to state the outcomes of patients who had withdrawn from the studies, we considered them to be treatment failures and included them in the analysis as such.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-11-07 13:44:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-11-07 13:43:02 +0000" MODIFIED_BY="[Empty name]">
<P>For this fourth update we identified one additional, eligible study (<LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>). In reviewing the studies included in the review during the update process, we have excluded <LINK REF="STD-Mol-1991" TYPE="STUDY">Mol 1991</LINK> as, on closer inspection, it appears not to be a randomised trial. One study (<LINK REF="STD-Wille-2011" TYPE="STUDY">Wille 2011</LINK>) is awaiting assessment.</P>
<P>The following comparisons were made:</P>
<P>
<B>1. Grafts compared with standard care </B>
<BR/>1.1 Autograft compared with standard care (two trials) (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>).<BR/>1.2 Fresh or frozen allograft compared with standard care (five trials) (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>).<BR/>1.3 Bilayered human skin equivalent compared with standard care (two trials) (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>).<BR/>1.4 Single-layered dermal skin replacement compared with standard care (two trials) (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>).<BR/>1.5 Growth-arrested human keratinocytes and fibroblasts compared with placebo equivalent (one trial) (<LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>).</P>
<P>
<B>2. Comparison between grafts </B>
<BR/>2.1 Autograft compared with frozen allograft (one trial) (<LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>).<BR/>2.2 Autograft compared with xenograft (one trial) (<LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>).<BR/>2.3 Autograft delivered on porcine pads compared with autograft delivered on porcine gelatin microbeads (one trial) (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>).<BR/>2.4 Autograft compared with cultured keratinocyte autograft (one trial) (<LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>).<BR/>2.5 Frozen allograft compared with lyophilised keratinocyte allograft (one trial) (<LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Study setting</HEADING>
<P>Three studies involved both inpatients and outpatients (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>), one included inpatients only (<LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>) and five included outpatients only (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>). Eight studies provided insufficient data on population or setting (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diagnosis of venous ulceration</HEADING>
<P>Three studies failed to report the way in which venous ulceration was confirmed (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Mol-1991" TYPE="STUDY">Mol 1991</LINK>; <LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>). Four studies diagnosed venous ulceration by excluding arterial disease by means of a hand-held Doppler, together with clinical examination (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>). Nine studies excluded arterial disease on the basis of hand-held Doppler, and used an objective test of venous insufficiency, e.g. venous Doppler, Duplex or plethysmography (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion and exclusion criteria</HEADING>
<P>Inclusion and exclusion criteria were clearly listed in eight trials (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>). The external validity of the remaining nine trials could not be easily assessed (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>).</P>
<P>The majority of studies (15/17) included participants with ulcers which were 'hard to heal'. The means by which participants with 'hard to heal' ulcers were detected was either area/duration at baseline or during a washout period. Five studies recruited people with ulcers of longer than six months' duration (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>), and six studies used a three-month or 12-week qualifying period (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>). One study used a one-month duration inclusion criterion (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>). Two studies used a washout period, one of which included people whose ulcer failed to decrease in area by at least 30% with two weeks' compression (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>), while the other included those in whom ulcer area failed to decrease by 50% in 14 days (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>). Two trials did not describe attempts to exclude ulcers on the basis of chronicity (<LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study duration</HEADING>
<P>The studies had a variety of duration of active treatment and follow-up. <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>, for example, had eight weeks' treatment with the skin equivalent and six months' follow-up. The trial duration ranged from six weeks (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>) to 12 months (<LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>). Where there were differences in trial duration, the results from pooled studies should be interpreted cautiously.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sample size</HEADING>
<P>The sample sizes used in most of these trials were a major deficiency in their design. Only two trials described an a priori sample size calculation (<LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>). The sample size calculations performed by these authors sought to detect very large effect sizes, e.g. doubling the healing rate, and hence the required sample sizes were 40 (<LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>) and 80 (<LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>). Since it is unlikely that an effect size of this magnitude would be realised in a trial of an intervention for healing chronic wounds - where a RR of 1.1 is typical and up to 1.5 is rare - these sample size calculations may be unrealistic. Twelve trials included a maximum of 51 participants. The smallest included trial in this review had four participants (<LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>), while the largest had 309 participants (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Adverse events were reported by treatment group in four studies (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>, <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>). Other trials made general statements such as "no infections", or "no contact dermatitis", or failed to mention adverse effects (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-01 16:01:01 +0000" MODIFIED_BY="[Empty name]">
<P>Further details of each study are documented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and 'Risk of bias' summary figure (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<ALLOCATION MODIFIED="2011-11-01 16:00:52 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Randomisation sequence</HEADING>
<P>Only six trials reported a method of random sequence generation (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>) which ranged from computer-generated sequences to random number tables. No method of random sequence generation was reported in the remaining 11 trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>True randomisation with allocation concealment was explicitly reported in only one RCT (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>). Another trial reported that "randomisation schedules were held by the sponsor" and the allocation may, therefore, have been concealed (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>) but the judgement remains unclear. <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK> reported the use of sealed envelopes to conceal allocation however failed to specify whether the envelopes were opaque or sequentially numbered. The remaining 14 trials did not report the method of randomisation.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2011-11-01 16:00:56 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Participants/care givers</HEADING>
<P>Blinding of participants/care givers was achieved in two trials (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>) which mentioned double-blinding. Due to the nature of some of the interventions, it can be difficult to blind the participants/care givers. Patients receiving grafts can be subject to a surgical procedure and in this event this would make blinding almost impossible and this was the case in one trial (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>). Secondly, the method of application of some interventions meant that patients and care givers could be aware of the allocation (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>). <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK> reported its trial as open label. The remaining trials were judged to be unclear as there was insufficient information in the report to make a judgement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome assessment</HEADING>
<P>Blinded outcome assessment is rarely used in wound care studies as it can be difficult to disguise a graft - particularly a pinch or split-thickness graft - as these leave a characteristic pattern even in the fully healed state (sometimes described as a cobblestone appearance). Nevertheless, various attempts were made to blind the outcome assessment. Five studies (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>) reported blinding of outcome assessor by using various means such as identical dressings (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>), measuring outcomes using a remote computerised system (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>) or by blinding the data directly (<LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>). The remaining trials involving a form of surgical intervention made blinding outcome assessment impossible (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>). The rest of the trials provided insufficient evidence to ascertain whether outcome assessors were blind.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-11-01 16:00:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intention to treat (ITT) analysis, in which people are analysed in the group to which they were allocated, regardless of whether or not they received the allocated treatment, is the most robust analysis to conduct in an effectiveness trial. An ITT analysis of a surgical treatment, such as grafting, requires people to be analysed in the surgery group even if they did not receive the treatment (e.g. change of mind, got better on waiting list, became unfit for surgery). Such an analysis is necessary to maintain the balanced prognosis in the two groups achieved by randomisation, and any systematic exclusion of some participants from the analysis threatens the validity of the subsequent results. The alternative, a per-protocol analysis, includes people in the analysis according to the treatment they actually received and their availability at follow-up. In seven trials, all randomised participants were included in and accounted for in the final analysis (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>). In four trials, there were dropouts and withdrawals but were assessed to be low risk of bias in this domain as they accounted for 10% or fewer of the sample size (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>). The trial by <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK> reported losses to follow-up amounting to around 19% which was adjudged to be high risk of bias. The trials by <LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK> and <LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK> were only available in abstract form, and subsequent, fuller reports may contain more information about the fate of withdrawals. The number of withdrawals from a study can affect the internal validity. If there is a high proportion of withdrawals in comparison to the event rate, one cannot be confident of the result. In these trials, follow-up rates ranged from 81% (<LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>) to 100% (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>) and in two studies the number of withdrawals was not stated (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>) with no information on this supplied from authors.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-11-01 16:00:59 +0000" MODIFIED_BY="[Empty name]">
<P>All trials reported their primary and secondary (if applicable) outcomes adequately with no suggestion of selective outcome reporting. All trials had reasonable primary outcomes with no omissions or absences.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-11-01 16:01:01 +0000" MODIFIED_BY="[Empty name]">
<P>In studies of treatment of venous leg ulcers, it is essential to ensure baseline comparability for ulcer area, and duration and history of previous ulceration, as these factors are likely to affect the outcome (<LINK REF="REF-Margolis-2004" TYPE="REFERENCE">Margolis 2004</LINK>; <LINK REF="STD-Skene-1992" TYPE="STUDY">Skene 1992</LINK>). </P>
<P>Fifteen studies reported ulcer area at baseline; the remaining two did not (<LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>). There were obvious imbalances in the ulcer areas in eight trials at baseline (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>) identified by simple inspection of the baseline characteristics. Authors commonly stated there was "no significant difference" in baseline ulcer areas after applying statistical tests to compare these (inappropriate since, by definition, it is already known that where participants were randomised any baseline imbalance has arisen by chance). Only one of the included studies reported using ulcer area as a covariate in the analysis to account for any differences in the distribution of important predictors such as ulcer area or duration at randomisation (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>). In large trials, randomised allocation should ensure that the mean wound size and variance in each group is similar. In a small trial, random allocation is unlikely to result in an even distribution of wound sizes and incorporating area into the analysis is recommended. If baseline data are not given, then it is not possible to determine the direction of bias and the validity of the result cannot be determined.</P>
<P>The duration of ulceration by allocation group was reported in fifteen trials (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>; <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>) and, of these, three had well-balanced ulcer duration in the two groups (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>). In five trials the control group had ulcers of longer duration (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>). In six other studies there were variations in ulcer duration between the study groups (<LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>; <LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>; <LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>). Only one of the included studies reported using ulcer duration as a covariate in the analysis to account for any differences in the distribution of ulcer duration at randomisation (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>).<B> </B>
</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-11-07 13:44:26 +0000" MODIFIED_BY="[Empty name]">
<P>The results will be presented in the following comparisons.</P>
<P>
<B>1. Grafts compared with standard care </B>
<BR/>1.1 Autograft compared with standard care (two trials) (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>).<BR/>1.2 Fresh or frozen allograft compared with standard care (five trials) (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>).<BR/>1.3 Bilayered human skin equivalent compared with standard care (two trials) (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>).<BR/>1.4 Single-layered dermal skin replacement (two trials) (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>).<BR/>1.5 Growth-arrested human keratinocytes and fibroblasts compared with placebo equivalent (one trial) (<LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>).<BR/>
</P>
<P>
<B>2. Comparison between grafts </B>
<BR/>2.1 Autograft compared with frozen allograft (one trial) (<LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>).<BR/>2.2 Autograft compared with xenograft (one trial) (<LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>).<BR/>2.3 Autograft delivered on porcine pads compared with autograft delivered on porcine gelatin microbeads (one trial) (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>).<BR/>2.4 Autograft compared with cultured keratinocyte autograft (one trial) (<LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>).<BR/>2.5 Frozen allograft compared with lyophilised keratinocyte allograft (one trial) (<LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Grafts compared with standard care</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Autografts compared with standard care of hydrocolloid dressing</HEADING>
<P>Two trials compared split-thickness autografts with a hydrocolloid dressing in 102 participants (<LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK>; <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>). In <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>, both groups had vein surgery and they found no evidence of a significant benefit for autografts over a dressing in this small trial (102 participants) (risk ratio (RR) of healing with autografts 0.89, 95% confidence interval (CI) 0.34 to 2.31) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK> reported a large difference in healing rates (RR of healing 42.93, 95% CI 2.72 to 677.16) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Looking at these trials together, there was very high heterogeneity (I² = 93%), therefore pooling was inappropriate. Both had follow-up periods of six months but the control groups (both receiving compression) had differing healing rates: 0% in <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK> (which is lower than commonly reported in other trials) and 38% in <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK>. This might indicate a different severity of ulcers seen in the <LINK REF="STD-Jankunas-2007" TYPE="STUDY">Jankunas 2007</LINK> group, or potentially reflect performance bias.</P>
<P>These trials provide no firm evidence of benefit rather than firm evidence of lack of benefit. At baseline, the <LINK REF="STD-Warburg-1994" TYPE="STUDY">Warburg 1994</LINK> trial had larger ulcers in the skin graft group, which may have biased the results against grafting, or it may indicate that allocation was subverted as there was no indication whether allocation was concealed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Fresh or frozen allografts compared with standard care of low-adherent dressing or hydrocolloid</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Frozen allografts</HEADING>
<P>Three trials compared frozen allografts with control dressings (Mepitel, petroleum jelly-impregnated gauze or hydrocolloid) in 80 participants (<LINK REF="STD-Lindgren-1998" TYPE="STUDY">Lindgren 1998</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>; <LINK REF="STD-Teepe-1993" TYPE="STUDY">Teepe 1993</LINK>). Pooling the three trials using a fixed-effect model (Chi² 0.76; degrees of freedom (df) = 1; P value 0.38; I² = 0%) showed that there was no significant difference in healing with allografts over standard care (RR 1.62, 95% CI 0.79 to 3.33) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fresh allografts</HEADING>
<P>Three trials (45 participants) compared fresh allografts with standard care of non-adherent dressing soaked in culture medium, or petroleum jelly-impregnated gauze (<LINK REF="STD-Burdge-2000" TYPE="STUDY">Burdge 2000</LINK>; <LINK REF="STD-Duhra-1992" TYPE="STUDY">Duhra 1992</LINK>; <LINK REF="STD-Paquet-2005" TYPE="STUDY">Paquet 2005</LINK>). Pooling these three trials using a fixed-effect model (Chi² 0.02; df = 1; P value 0.88; I² = 0%) showed that there was no significant difference in healing with allografts over standard care (RR 3.73, 95% CI 0.80 to 17.45) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Pooled analysis: pooling all five trials (125 participants) using a fixed effect model (Chi² 1.65; df =3; P value 0.65; I² = 0%) indicated significantly higher healing rates with allografts than dressings (RR 2.00, 95% CI 1.04 to 3.84) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Given the methodological problems with these trials, this result should be confirmed by large, well-designed and conducted trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Bilayered human skin equivalent compared with standard care of foam or placebo dressing</HEADING>
<P>Two trials (345 participants) compared a bilayered skin equivalent with standard care of foam or a dressing made to look like the skin equivalent (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>). Apligraf (Novartis), used by <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>, is described as having a lower layer to replace the dermis and an upper layer to replace the epidermis. Orcel (Ortec International), used by <LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>, has a collagen matrix onto which donor fibroblast and keratinocytes are seeded and cultured. These were compared with a simple dressing underneath compression therapy (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>; <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>). <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK> randomised 309 participants, of whom 275 were available for evaluation of efficacy. <LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK> described a trial in which 36 people with "hard to heal" ulcers were randomised. <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK> reported that the ulcers of 92/146 (63%) participants in the treatment group had healed completely at six months compared with 63/129 (49%) in the control group. In the second trial, 12/17 (71%) of people with tissue-engineered skin plus compression had healed completely at six months compared with 7/19 (37%) in the compression therapy group (<LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK>).</P>
<P>Pooling the results from these two trials using a fixed-effect model (Chi² = 0.55; df = 1; P value 0.46; I² = 0%) yields a RR of healing with the artificial skin compared with simple dressings of 1.51 (95% CI 1.22 to 1.88) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The increase in healing rate from approximately 40% to 60% represents a number needed to treat to benefit (NNTB) of 1/0.2, or 5 for six months' treatment. This means that five participants would need to be treated with artificial skin rather than a simple dressing, in order for one additional ulcer to heal at six months. These two trials provide reasonable evidence that a greater proportion of venous ulcers heal with artificial skin than a simple dressing. The lack of an intention-to-treat analysis for the <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK> trial reduces our certainty of the results. However, as participants in the trial who were not accounted for in the analysis may have dropped out for reasons related to the treatments, we contacted the authors to ask if data were available for an intention-to-treat analysis; they replied that the study sponsor had these data and had not made them available to the authors.</P>
<P>There was no concurrent economic analysis in the trials comparing tissue-engineered skin with standard care.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Single-layered dermal skin replacement compared with low-adherent dressing</HEADING>
<P>Two trials (71 participants) compared a single-layered dermal replacement (<LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK>; <LINK REF="STD-Omar-2004" TYPE="STUDY">Omar 2004</LINK>) with standard care of four-layer compression and a low-adherent dressing. Both trials evaluated Dermagraft (Smith and Nephew), described as a human fibroblast-derived dermal replacement; the origin of the cells being newborn foreskin. The first study compared three different regimens with standard care (12 pieces, four pieces or one piece of Dermagraft (Smith and Nephew), and the second trial compared the four-piece regimen with standard care. There was no evidence of benefit associated with 12 pieces of dermal skin replacement (weekly for 11 weeks) compared with standard care in the small (26 participants) <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK> trial (RR 2.5, 95% CI 0.59 to 10.64) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). There was no evidence of overall benefit associated with four pieces of dermal skin replacement (at baseline, one, four and eight weeks) in the two studies (RR 3.04, 95% CI 0.95 to 9.68) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), when pooled using a fixed-effect model (44 participants). There was no evidence of benefit associated with one piece of dermal skin replacement (at baseline) compared with standard care in the <LINK REF="STD-Krishnamoorthy-2003" TYPE="STUDY">Krishnamoorthy 2003</LINK> trial, which made this comparison in 26 people (RR 0.46, 95% CI 0.05 to 4.53) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>There is therefore insufficient evidence, based on two small studies, that single-layered dermal skin replacement heals venous ulcers more quickly than a simple low-adherent dressing.<B> </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Growth-arrested human keratinocytes and fibroblasts compared with placebo equivalent</HEADING>
<P>One trial (<LINK REF="STD-Goedkoop-2010" TYPE="STUDY">Goedkoop 2010</LINK>) compared growth-arrested human keratinocytes and fibroblasts (HP802-247) with placebo equivalent in 110 participants. This multi-centre, double-blind study randomised participants to seven treatment groups that varied in the composition of the intervention (ratio of keratinocytes: fibroblasts and the concentration of cells per intervention). The results showed that percentage of ulcers healed at 12 and 24 weeks were greater in participants receiving the interventions compared with placebo in all comparisons. For the purposes of the analysis we combined the results of the six intervention groups and compared them with the placebo group; there was no statistically significant difference between the two groups at either 12 weeks or 24 weeks (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparisons between skin graft</HEADING>
<P>Five trials compared an autograft (such as split-thickness mesh grafts) with other grafting methods.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Autograft compared with frozen allograft</HEADING>
<P>One trial with 92 participants compared autograft with frozen allograft and found no difference in healing rates (<LINK REF="STD-Tausche-2003" TYPE="STUDY">Tausche 2003</LINK>), expressed as proportions healed (RR 1.04, 95% CI 0.56 to 1.94) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) or percentage reduction in area (14.37% greater reduction with autograft, 95% CI -13.76 to 42.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Autograft compared with xenografts</HEADING>
<P>We identified one trial (51 people) comparing pinch grafts with a porcine dermis (xenograft) dressing (<LINK REF="STD-Poskitt-1987" TYPE="STUDY">Poskitt 1987</LINK>). The increase in ulcers healed at 12 weeks with pinch grafting (72% (18/25) compared with 46% (13/28) xenograft) just missed the traditional cut-off for statistical significance (Chi² 3.55; df = 1; P value 0.06). The risk ratio for healing with autograft was 1.55 (95% CI 0.97 to 2.47) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). There was, however, a significant benefit associated with pinch grafts when the data were analysed by time to healing and the number of ulcers healed (authors' log rank Chi² 4.1; P value &lt; 0.05). The larger and older ulcers were in the pinch graft group (difference of 10 cm² in mean area and 10 months in mean duration) biasing the study against pinch grafting and therefore increasing our confidence in the result. It is not clear what the withdrawal rate was, as it was stated that 51 patients with 60 ulcers entered the study but as four people "refused the study", 53 legs were "available for randomisation". If the four refusals were post-randomisation refusals of graft or xenograft, then they should have been included in the analysis on an intention-to-treat basis regardless of the treatment received. The exclusion of these participants threatens the validity of the results. In addition, it is not clear whether the authors accounted for the fact that there were more legs than participants in the study. The trial did randomise legs rather than participants, but the subsequent analysis should not have assumed that each piece of information, e.g. healing time, was independent, as data from both legs of the same participant are not independent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Autograft delivered on porcine pads compared with autograft delivered on porcine gelatin microbeads</HEADING>
<P>One trial made this comparison in 10 people (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>). There was no difference in the number of people healed at the end of the trial (RR 1.0, 95% CI 0.08 to 11.93), with only 20% healing in each group (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Autograft compared with cultured autologous keratinocytes</HEADING>
<P>One trial compared Epidex, an autologous epidermal equivalent grown from the outer root sheath keratinocytes of plucked hair follicles, with a meshed autograft in 92 people (reported outcomes only on 77) (<LINK REF="STD-Salomon-2002" TYPE="STUDY">Salomon 2002</LINK>). There was no statistically significant difference in the number of people healed at the end of the trial (RR 1.04, 95% CI 0.56 to 1.94: our intention-to-treat analysis - assuming the non-healing of dropouts)(<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Frozen allograft compared with lyophilised keratinocyte</HEADING>
<P>One trial (50 people) compared a cryopreserved graft with lyophilised keratinocytes (<LINK REF="STD-Navratilova-2004" TYPE="STUDY">Navratilova 2004</LINK>). This found no difference in healing rates at the end of the trial (RR 1.05, 95% CI 0.81 to 1.36) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-03-29 11:17:22 +0100" MODIFIED_BY="[Empty name]">
<P>Concerns regarding the quality of (and therefore risk of bias inherent in) the included trials affect the strength of the conclusions we can make. The quality of reporting was generally poor; many trials did not report inclusion criteria, so we could not tell whether the patients in the various trials were similar or representative. Little information was given on randomisation methods, and whether trialists took steps to conceal allocation from those recruiting patients into the studies. Other common methodological flaws were lack of baseline comparability and lack of blinded outcome assessment. Withdrawals and adverse events were poorly reported. Lack of clarity about withdrawals and the tendency to conduct per-protocol analyses - rather than intention-to-treat analyses - mean that the results reported in the original trial documentation may be biased.</P>
<P>The clearest conclusion is that bilayer tissue-engineered skin increased the chance of healing compared with a simple dressing made to look like the skin equivalent (under compression). A meta-analysis of five small trials comparing fresh or frozen allografts found a higher healing rate with allografts than standard care, but these small trials were of poor quality and hence this result should be treated with caution. Most of the trials provided insufficient evidence of benefit, rather than firm evidence of lack of benefit. Fifteen of the 17 included trials were under-powered and, therefore, clinically important differences were unlikely to reach statistical significance and be detected. This point is illustrated by the trial by <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>, who found that human skin equivalent increased the risk of healing by 14% (from 49% to 63% at six months). If we consider that a 14% difference in healing is worthwhile, a sample size calculation determines that 210 participants would be needed in each group to detect such a difference. This estimate is based on 80% power (i.e. an 80% probability that this difference will be detected if it really exists) and a 5% probability of concluding that a difference does exist when, in fact, it does not. Having said this, <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK> actually came quite close to this sample size estimate; however, the other 16 trials in this review were significantly smaller.</P>
<P>A number of outcome measures that may be of importance to patients were not measured, e.g. the pain of a pinch graft, or the creation of the graft site, which gives the patient an additional wound and may impinge on quality of life. Graft sites are at risk of infection and management of them increases costs. The cosmetic appearance of graft sites may also be problematic, since pinch grafts result in the creation of a cobblestone-like irregular surface.</P>
<P>The use of autologous keratinocytes in patients with venous leg ulcers causes several difficulties; each patient undergoes a biopsy, followed by a necessary delay of three to four weeks whilst the cells are cultivated. Furthermore, cultured keratinocytes from older individuals grow to confluence more slowly, and produce cultures that have reduced mitogen responsiveness and life spans - characteristics that are likely to persist after grafting in the wound bed (<LINK REF="REF-Phillips-1989" TYPE="REFERENCE">Phillips 1989</LINK>). It is worth emphasising, however, that whilst adult cells may be slower initially to culture, once grown, they produce the same amount of growth factors as neonatal cells (<LINK REF="REF-Compton-1995" TYPE="REFERENCE">Compton 1995</LINK>). The culture lifetime of keratinocytes declines with the age of the donor; this may be due in part to loss of holoclones, the clonal cell type that has the greatest growth potential with increasing age (<LINK REF="REF-Barrandon-1987" TYPE="REFERENCE">Barrandon 1987</LINK>). Moreover, cultured neonatal keratinocytes release factors that stimulate the growth of other keratinocytes, whereas adult keratinocytes do not.</P>
<P>Allografts and bioengineered skin equivalents allow patients with chronic venous ulceration the chance to receive skin grafts without the additional injuries caused by harvesting, a stay in hospital, or the morbidity and mortality risks of anaesthesia. However, the preparation of ulcers for skin grafts is an important factor, since clean and granulating wounds are required for the procedure (<LINK REF="REF-Apligraf-2010" TYPE="REFERENCE">Apligraf 2010</LINK>). Whilst venous ulcers frequently occur on, or around, the ankle, these ulcers may not be suitable for artificial skin since it is difficult to anchor and immobilise the material on these areas. However, since the application of artificial skin is a noninvasive procedure that can be performed on an outpatient basis, it may offer significant advantages over split-thickness skin grafting in that it avoids the creation of a painful donor site, which can take a long time to heal in elderly people. Issues such as cost and the need for specialised storage facilities for artificial skin (which needs to be kept frozen until used) were not discussed by either <LINK REF="STD-Brown_x002d_Etris-2000" TYPE="STUDY">Brown-Etris 2000</LINK> or <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>. Some people may not accept the use of xenografts because of religious of cultural beliefs (<LINK REF="REF-Enoch-2005" TYPE="REFERENCE">Enoch 2005</LINK>).</P>
<P>Schonfeld et al (<LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK>) developed an economic model to estimate the costs and benefits of using Apligraf (Novartis)/Graftskin compared with a simple zinc oxide dressing (Unna's boot - standard therapy in the USA); both groups receiving compression. This model used healing data from <LINK REF="STD-Falanga-1998" TYPE="STUDY">Falanga 1998</LINK> and estimated that direct treatment costs were USD 20,041 per annum for people treated with Apligraf, compared with USD 27,493 for people treated with standard care. The higher treatment cost for Apligraf (USD 1425 per application) compared with Unna's boot (USD 12.05 per application) was more than offset by the need for fewer dressing changes, as a greater proportion of people healed more quickly with Apligraf. The results from this model need to be confirmed in a prospective economic analysis.</P>
<P>Compression therapy remains the mainstay of treatment for venous ulceration in clinical practice, with high-compression therapy being more effective at healing than low-compression systems. However, some 20% of ulcers remain unhealed after more than 50 weeks of appropriate compression therapy (<LINK REF="REF-Barwell-2004" TYPE="REFERENCE">Barwell 2004</LINK>). Margolis et al (<LINK REF="REF-Margolis-2004" TYPE="REFERENCE">Margolis 2004</LINK>) was able to demonstrate, using the parameters of ulcer size and duration, that longstanding ulcers had only a 22% chance of healing at 24 weeks compared with small recent ulcers, which had a 71% chance. Therefore, it may be appropriate to identify those patients with "hard-to-heal" ulcers early, so that they may benefit from early adjunctive therapies such as grafting, rather than using this therapy as an early adjunct in ulcers that are not classed as recalcitrant where it may be unnecessary.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-11-30 11:05:10 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-06 09:55:03 +0000" MODIFIED_BY="[Empty name]">
<P>Bilayer tissue-engineered skin replacement, used with compression, increases the rate of healing of venous leg ulcers compared with simple dressings used with compression. There is insufficient evidence for the effectiveness of any other skin graft material or procedure for the treatment of venous leg ulcers.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-11-30 11:05:10 +0000" MODIFIED_BY="Sally EM Bell-Syer">
<P>Large randomised controlled trials (RCTs) comparing the interventions listed below would be valuable:</P>
<UL>
<LI>Autografts: pinch grafting plus compression compared with compression alone.</LI>
<LI>Allografts: cultured allografts compared with simple dressings.</LI>
<LI>Bioengineered skin replacements: effectiveness and cost-effectiveness of the various artificial skin products compared with simple dressings.</LI>
</UL>
<P>Methods to identify people with ulcers amenable to treatment with skin grafts need to be developed, e.g. selecting people without infection (if this is shown to increase the probability of successful graft take), and identifying people who will heal without adjuvant therapies such as skin grafts.</P>
<P>New RCTs should follow CONSORT reporting guidelines and ensure that they report baseline comparability of treatment groups for important prognostic factors (such as ulcer area and duration); measure and analyse time to complete healing by appropriate (survival) methods; and report pain, acceptability, cosmetic outcomes, adverse events such as infection rates and recurrence, cost-effectiveness and quality of life.</P>
<P>Research is also needed into the identification of patients for whom grafting may be required and is effective. We know little about the feasibility of using artificial skin in primary care and other 'low tech' settings.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-11-30 11:05:10 +0000" MODIFIED_BY="Sally EM Bell-Syer">
<P>The review authors would like to thank:</P>
<UL>
<LI>the Cochrane Wounds Group referees (Kate Ballard, Alun Davies, Christine Moffatt and Julie Shaw) who commented on the protocol;</LI>
<LI>the Cochrane Wounds Group referees (Malcolm Brewster, Jacqueline Dinnes and Mark Fenton) and Editor (Mieke Flour) who commented on the original review;</LI>
<LI>the Cochrane copy editor Elizabeth Royle; and</LI>
<LI>Sally Stapley, working with the Cochrane Wounds Group, who facilitated the third update of this review.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-12-05 08:07:39 +0000" MODIFIED_BY="Sally EM Bell-Syer">
<P>	Andrea Nelson was co-applicant and trial co-ordinator for one of the trials included in this review (Iglesias 2004); this trial was commissioned after the first version of this review was completed. Andrea Nelson was trial co-ordinator and author of the main publication for one of the trials included in this review (Nelson 2007a).</P>
<P>	June Jones and Aws Al-Hity - none.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-11-30 11:05:10 +0000" MODIFIED_BY="Sally EM Bell-Syer">
<P>June Jones (JEJ) and Andrea Nelson (EAN) checked the search results for inclusion and exclusion. JEJ extracted data from the included trials and this was checked by EAN. Analysis, data entry, drafting and editing of the review were undertaken by both JEJ and EAN. Updating the review was undertaken by both JEJ and EAN.<BR/>Aws Al-Hity contributed to the fourth update by checking the search results, extracting data and undertaking a risk of bias assessment on all included studies and adding these data to the review update.<BR/>JEJ is the guarantor for the review.</P>
<SUBSECTION>
<HEADING LEVEL="5">Contributions of editorial base:</HEADING>
<P>Nicky Cullum: edited the review, advised on methodology, interpretation and review content. Approved the final review and review update prior to submission.<BR/>Liz McInnes, Editor: approved the recent updated review for submission.<BR/>Sally Bell-Syer: co-ordinated the editorial process. Advised on methodology, interpretation and content. Edited and copy edited the review and the updated review.<BR/>Ruth Foxlee: designed the search strategy, ran the searches and edited the search methods section for the update.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-10-29 14:14:52 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-08-01 08:59:37 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-08-01 08:59:37 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-08-01 08:59:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brown_x002d_Etris-2000" MODIFIED="2012-03-29 10:05:35 +0100" MODIFIED_BY="[Empty name]" NAME="Brown-Etris 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-29 10:05:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Brown-Etris M , Shields DK, Galluzzi KE et al. Preliminary clinical outcomes on the use of composite cultured skin for the healing of venous ulcers. The 13th Annual Symposium on Advanced Wound Care &amp;amp; 10th Annual Medical Research Forum on Wound Repair. USA: HMP Communications, LLC., 2000:D4. (growth factors/skin grafting composite cultured skin v standard care; Full; HS).&lt;/p&gt;" NOTES_MODIFIED="2012-03-29 10:05:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brown-Etris M, Shields DK, Galluzzi KE, Steinberg JS, Shalen AB, Barnes HR, et al</AU>
<TI>Preliminary clinical outcomes on the use of composite cultured skin for the healing of venous ulcers</TI>
<SO>13th Annual Symposium on Advanced Wound Care and 10th Annual Medical Research Forum on Wound Repair; 2000, 1-4 April; Dallas, Texas</SO>
<YR>2000</YR>
<PG>D5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burdge-2000" MODIFIED="2012-03-29 10:06:58 +0100" MODIFIED_BY="[Empty name]" NAME="Burdge 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-29 10:06:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Burdge J, Cope F, Abbruzzese B, Wille J. Long-term healing of venous stasis ulcers treated with serum-free cultured epidermal autografts. Eleventh Annual Meeting and Educational Symposuim Wound Healing Society. 2001:146. (skin grafting cultured epidermal autograft v control; HS).&lt;/p&gt;" NOTES_MODIFIED="2012-03-29 10:06:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burdge J, Cope F, Abbruzzese B, Wille J</AU>
<TI>Long-term healing of venous stasis ulcers treated with serum-free cultured epidermal autografts</TI>
<SO>Eleventh Annual Meeting and Educational Symposuim Wound Healing Society; 2001, 16-18 May; Albuquerque, New Mexico</SO>
<YR>2001</YR>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-29 10:06:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Burdge J, Swanson N, Pittelkow M, Cope F, Abbruzzese B, Schaefer S, et al</AU>
<TI>Successful treatment of venous stasis leg ulcers with a cultured autologous epidermal graft</TI>
<SO>Wound Healing Society Educational Symposium; 2000, 4-6 June; Toronto, Canada</SO>
<YR>2000</YR>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duhra-1992" NAME="Duhra 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duhra P, Blight A, Mountford E, Cheshire I, Withers A, Ilchyshyn A</AU>
<TI>A randomized controlled trial of cultured keratinocyte allografts for chronic venous ulcers</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>189-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falanga-1998" MODIFIED="2012-03-29 10:08:12 +0100" MODIFIED_BY="[Empty name]" NAME="Falanga 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-29 10:07:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atillasoy E</AU>
<TI>The safety and efficacy of Graftskin (APLIGRAF) in the treatment of venous leg ulcers: a multicenter, randomized, controlled clinical trial</TI>
<SO>Wounds - A Compendium of Clinical Research and Practice</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>Suppl A</NO>
<PG>20A-6A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, et al</AU>
<TI>Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent</TI>
<SO>Archives of Dermatology</SO>
<YR>1998</YR>
<VL>134</VL>
<PG>293-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falanga V, Sabolinski M</AU>
<TI>A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-29 10:08:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sabolinski M, Rovee D, Parenteau N, Mulder G, Jensen J</AU>
<TI>The efficacy and safety of graftskin for the treatment of chronic venous ulcers</TI>
<SO>5th Annual Meeting of the Wound Healing Society and the Regeneration Forum; 1994, 27-30 April; Minneapolis USA</SO>
<YR>1995</YR>
<PG>78</PG>
<ED>Lindblad WJ</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabolinski ML, Alvarez O, Auletta M, Mulder G, Parenteau NL</AU>
<TI>Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers</TI>
<SO>Biomaterials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>311-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schonfeld WH, Villa KF, Fastenau JM, Mazonson PD, Falanga V</AU>
<TI>An economic assessment of APLIGRAF (Graftskin) for the treatment of hard-to-heal venous leg ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2000</YR>
<VL>8</VL>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goedkoop-2010" MODIFIED="2012-03-29 10:08:51 +0100" MODIFIED_BY="[Empty name]" NAME="Goedkoop 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-29 10:08:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goedkoop R, Juliet R, You PHK, Daroczy J, De Roos K, Lijnen R, et al</AU>
<TI>Wound stimulation by growth-arrested human keratinocytes and fibroblasts: HP802-247, a new-generation allogenic tissue engineering product</TI>
<SO>Dermatology</SO>
<YR>2010</YR>
<VL>220</VL>
<PG>114-20</PG>
<IDENTIFIERS MODIFIED="2011-07-14 12:13:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jankunas-2007" MODIFIED="2012-08-01 08:59:37 +0100" MODIFIED_BY="[Empty name]" NAME="Jankunas 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-01 08:59:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jankunas V, Bagdonas R, Samsanavicius D, Rimdeika R</AU>
<TI>An analysis of the effectiveness of skin grafting to treat chronic venous leg ulcers</TI>
<SO>Wounds: A Compendium of Clinical Research and Practice</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>5</NO>
<PG>128-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-19 11:42:37 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krishnamoorthy-2003" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Krishnamoorthy 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harding KG, Brassard A, Dolynchuck K, Leaper D, Poskitt K, Sibbald RG</AU>
<TI>A pilot study to determine the effect of human dermal replacement in treating hard-to-heal venous leg ulcers</TI>
<SO>Proceedings of the 13th Annual Symposium on Advanced Wound Care &amp; 10th Annual Medical Research Forum on Wound Repair. USA: HMP Communications, LLC</SO>
<YR>2000</YR>
<PG>C68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krishnamoorthy L, Harding KG, Griffiths D, Moore K, Leaper D, Poskitt K, et al</AU>
<TI>The clinical and histological effects of Dermagraft® in the healing of chronic venous leg ulcers</TI>
<SO>Phlebology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>1</NO>
<PG>12-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindgren-1998" NAME="Lindgren 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindgren C, Marcusson J, Toftgard R</AU>
<TI>Treatment of venous leg ulcers with cryopreserved cultured allogeneic keratinocytes: a prospective open controlled study</TI>
<SO>British Journal of Dermatology</SO>
<YR>1998</YR>
<VL>139</VL>
<PG>271-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" NAME="Liu 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Liu JY, Hafner J, Dragieva G, Seifert B, Burg G. Autologous cultured keratinocytes on porcine gelatin microbeads effectively heal chronic venous leg ulcers. Wound Repair and Regeneration 2004 12 2 148-56.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu JY, Hafner J, Dragieva G, Seifert B, Burg G</AU>
<TI>Autologous cultured keratinocytes on porcine gelatin microbeads effectively heal chronic venous leg ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>2</NO>
<PG>148-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navratilova-2004" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Navratilova 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Navratilova Z, Slonkova V, Semradova V, Adler J. Cryopreserved and lyophilized cultured epidermal allografts in the treatment of leg ulcers: A pilot study. Journal of the European Academy of Dermatology &amp;amp; Venereology 2004 18 2 173-179.&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Navratilova Z, Slonkova V, Semradova V, Adler J</AU>
<TI>Cryopreserved and lyophilized cultured epidermal allografts in the treatment of leg ulcers: a pilot study</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>2</NO>
<PG>173-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Navratilova Z. Cryopreserved and lyophilized cultured epidermal allografts in the treatment of leg ulcers. Abstract. In: 20th World Congress of Dermatology. 2002.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Navratilova Z</AU>
<TI>Cryopreserved and lyophilized cultured epidermal allografts in the treatment of leg ulcers</TI>
<SO>20th World Congress of Dermatology</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omar-2004" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Omar 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Omar A A, Mavor A I, Jones A M, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. European Journal of Vascular and Endovascular Surgery 2004 27 6 666-72.&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omar AA, Mavor AI, Jones AM, Homer-Vanniasinkam S</AU>
<TI>Treatment of venous leg ulcers with Dermagraft</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>6</NO>
<PG>666-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paquet-2005" NAME="Paquet 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Paquet P, Quatresooz P, Braham C, Pi&amp;#233;rard GE. Tapping into the influence of keratinocyte allografts and biocenosis on healing of chronic leg ulcers: split-ulcer controlled pilot study. Dermatologic Surgery : official publication for American Society for Dermatologic Surgery 2005 31 4 431-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paquet P, Quatresooz P, Braham C, Piérard GE</AU>
<TI>Tapping into the influence of keratinocyte allografts and biocenosis on healing of chronic leg ulcers: split-ulcer controlled pilot study</TI>
<SO>Dermatologic Surgery</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>4</NO>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poskitt-1987" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Poskitt 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poskitt K, James A, Lloyd-Davies E, Walton J, McCollum C</AU>
<TI>Pinch skin grafting or porcine dermis in venous ulcers: a randomised clinical trial</TI>
<SO>British Medical Journal</SO>
<YR>1987</YR>
<VL>294</VL>
<PG>674-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salomon-2002" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Salomon 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Salomon D</AU>
<TI>Epidex: a new treatment for recalcitrant chronic leg ulcers (abstract)</TI>
<SO>20th World Congress of Dermatology; 2002, 1-5 July; Paris</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-19 11:15:16 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tausche-2003" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Tausche 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tausche A, Skaria M, Bohlen L, Liebold K , Hafner J, Friedlein H, Meurer M, Goedkoop RJ, Wollina U, Salomon D, Hunziker T. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair and Regeneration 2003 11 4 248-52.&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tausche A, Skaria M, Bohlen L, Liebold K, Hafner J, Friedlein H, et al</AU>
<TI>An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>4</NO>
<PG>248-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teepe-1993" NAME="Teepe 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teepe R, Roseeuw D, Hermans J, Koebrugge E, Altena T, Coninck A, et al</AU>
<TI>Randomized trial comparing cryopreserved cultured epidermal allografts with hydrocolloid dressings in healing chronic venous ulcers</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>6</NO>
<PG>982-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warburg-1994" NAME="Warburg 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warburg F, Danielsen L, Madsen S, Raaschou H, Munkvad S, Jensen R, et al</AU>
<TI>Vein surgery with or without skin grafting versus conservative treatment for leg ulcers</TI>
<SO>Acta Dermatologica Venereologica (Stockholm)</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>4</NO>
<PG>307-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-03-29 10:27:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahnlide-1997" NAME="Ahnlide 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahnlide I, Bjellerup M</AU>
<TI>Efficacy of pinch grafting in leg ulcers of different aetiologies</TI>
<SO>Acta Dermatologica Venereologica (Stockholm)</SO>
<YR>1997</YR>
<VL>77</VL>
<PG>144-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altman-1997" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Altman MI. Treatment of venous ulcers with human skin equivalent [letter] J Am Podiatr Med Assoc. 1997 Aug; 87(8): 392-4&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altman MI</AU>
<TI>Treatment of venous ulcers with human skin equivalent [letter]</TI>
<SO>Journal of the American Podiatric Medical Association</SO>
<YR>1997</YR>
<VL>87</VL>
<NO>8</NO>
<PG>392-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1959" NAME="Andersen 1959" YEAR="1959">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen MN, Stephens JG</AU>
<TI>A controlled study of surgical treatment and pathogenesis of stasis ulcers</TI>
<SO>Annals of Surgery</SO>
<YR>1959</YR>
<VL>150</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beele-1991" NAME="Beele 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Beele H, Naeyaert JM, Goeteyn M, De Mil M, Kint A. Repeated cultured epidermal allografts in the treatment of chronic leg ulcers of various origins.Dermatologica. 1991; 183(1): 31-5&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beele H, Naeyaert JM, Goeteyn M, De Mil M, Kint A</AU>
<TI>Repeated cultured epidermal allografts in the treatment of chronic leg ulcers of various origins</TI>
<SO>Dermatologica</SO>
<YR>1991</YR>
<VL>183</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berretty-1979" NAME="Berretty 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Berretty PJ, Neumann HA, de Limpens AM, Cormane RH. Treatment of ulcers on legs from venous hypertension by split-thickness skin grafts. J Dermatol Surg Oncol. 1979 Dec; 5(12): 966-70&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berretty PJ, Neumann HA, de Limpens AM, Cormane RH</AU>
<TI>Treatment of ulcers on legs from venous hypertension by split-thickness skin grafts</TI>
<SO>Journal of Dermatology, Surgery and Oncology</SO>
<YR>1979</YR>
<VL>5</VL>
<NO>12</NO>
<PG>966-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyce-1995" MODIFIED="2009-08-21 13:44:41 +0100" MODIFIED_BY="[Empty name]" NAME="Boyce 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-21 13:44:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Boyce ST, Glatter R, Kitzmiller WJ. Case studies: treatment of chronic wounds with cultured skin substitutes. Ostomy Wound Manage. 1995 Mar; 41(2): 26-8, 30, 32 passim&lt;/p&gt;" NOTES_MODIFIED="2009-08-21 13:44:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyce ST, Glatter R, Kitzmiller WJ</AU>
<TI>Case studies: treatment of chronic wounds with cultured skin substitutes</TI>
<SO>Ostomy/Wound Management</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>2</NO>
<PG>26-8, 30, 32 passim</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calonge-1993" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Calonge 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Calonge H, Ruszczak Z, Stadler R</AU>
<TI>Human cultured epidermal auto- and allografts for wound healing. New method for in vitro epidermis reconstruction</TI>
<SO>Proceedings of the 1st Joint Meeting of the Wound Healing Society and the European Tissue Repair Society</SO>
<YR>22-25 August 1993. Amsterdam, The Netherlands</YR>
<PG>85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpentier-2009" MODIFIED="2012-03-29 10:21:27 +0100" MODIFIED_BY="[Empty name]" NAME="Carpentier 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-29 10:21:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpentier P</AU>
<TI>Venous ulcer: the final stage in chronic venous disease - managing it in 2009 (Pierre Fabre Symposium)</TI>
<SO>Phlebolymphology</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>1</NO>
<PG>28-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carver-1991" NAME="Carver 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Carver N, Leigh IM. Keratinocyte grafts and skin equivalents. Int J Dermatol. 1991 Aug; 30(8): 540-51&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carver N, Leigh IM</AU>
<TI>Keratinocyte grafts and skin equivalents</TI>
<SO>International Journal of Dermatology</SO>
<YR>1991</YR>
<VL>30</VL>
<NO>8</NO>
<PG>540-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2000" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang DW, Sancheez LA, Veith FJ, Wain RA, Okhi T, Suggs WD</AU>
<TI>Can a tissue-engineered skin graft improve healing of lower extremity foot wounds after revascularization?</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christiansen-1997" NAME="Christiansen 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Christiansen J, Ek L, Tegner E. Pinch grafting of leg ulcers. A retrospective study of 412 treated ulcers in 146 patients. Acta Derm Venereol. 1997 Nov; 77(6): 471-3&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christiansen J, Ek L, Tegner E</AU>
<TI>Pinch grafting of leg ulcers. A retrospective study of 412 treated ulcers in 146 patients</TI>
<SO>Acta Dermatologica Venereologica</SO>
<YR>1997</YR>
<VL>77</VL>
<NO>6</NO>
<PG>471-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clancy-1988" NAME="Clancy 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clancy JM, Shehade SA, Blight AE, Young KE, Levick PL</AU>
<TI>Treatment of leg ulcers with cultured epithelial grafts</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1988</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1356-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coney-1990" NAME="Coney 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Cony M, Donatien PH, Beylot C, Geniaux M, Maleville J, Bezian JH, Taieb A. Treatment of leg ulcers with an allogenic cultured-keratinocyte-collagen dressing. Clinical and Experimental Dermatology 1990;15: 410-414.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coney M, Donatien PH, Beylot C, Geniaux M, Maleville J, Bezian JH, et al</AU>
<TI>Treatment of leg ulcers with an allogenic cultured-keratinocyte-collagen dressing</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>1990</YR>
<VL>15</VL>
<PG>410-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahlstrom-1992" NAME="Dahlstrom 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Dahlstrom KK, Weis Fogh US, Medgyesi S, Rostgaard J, and Sorensen H. The use of autologous fibrin adhesive in skin transplantation. Plastic and Reconstructive Surgery 89(5), 968-72; discussion. 92. Full. topical agent/skin grafting.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlstrom KK, Weis Fogh US, Medgyesi S, Rostgaard J, Sorensen H</AU>
<TI>The use of autologous fibrin adhesive in skin transplantation</TI>
<SO>Plastic and Reconstructive Surgery</SO>
<YR>1992</YR>
<VL>89</VL>
<NO>5</NO>
<PG>968-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demling-2004" MODIFIED="2012-03-29 10:27:36 +0100" MODIFIED_BY="[Empty name]" NAME="Demling 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-03-29 10:27:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demling RH, Niezgoda JA, Haraway GD, Mostow EN</AU>
<TI>Small intestinal submucosa wound matrix and full-thickness venous ulcers: preliminary results</TI>
<SO>Wounds: A Compendium of Clinical Research and Practice</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fahey-1998" NAME="Fahey 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Fahey C. Experience with a new human skin equivalent for healing venous leg ulcers.J Vasc Nurs. 1998 Mar; 16(1): 11-5&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahey C</AU>
<TI>Experience with a new human skin equivalent for healing venous leg ulcers</TI>
<SO>Journal of Vascular Nursing</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>1</NO>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farah-2010" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Farah 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farah R, Davis MDP</AU>
<TI>Venous leg ulceration: a treatment update</TI>
<SO>Current Treatment Options in Cardiovascular Medicine</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>2</NO>
<PG>101-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halter-2003" NAME="Halter 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halter G, Kapfer X, Liewald F, Bischoff M</AU>
<TI>Vacuum-sealed mesh graft transplantation in chronic cutaneous ulcers of the lower leg</TI>
<SO>VASA</SO>
<YR>2003</YR>
<VL>32</VL>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1993" NAME="Harris 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Harris IR, Bottomley W, Wood EJ, Cunliffe WJ. Use of autografts for the treatment of leg ulcers in elderly patients. Clin Exp Dermatol. 1993 Sep; 18(5): 417-20&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris IR, Bottomley W, Wood EJ, Cunliffe WJ</AU>
<TI>Use of autografts for the treatment of leg ulcers in elderly patients</TI>
<SO>Clinical Experimental Dermatology</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>5</NO>
<PG>417-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-1988" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Harrison 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Harrison PV. Split-skin grafting of varicose leg ulcers- a survey and the importance of assessment of risk factors in predicting outcome from the procedure.Clin Exp Dermatol. 1988 Jan; 13(1): 4-6&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison PV</AU>
<TI>Split-skin grafting of varicose leg ulcers - a survey and the importance of assessment of risk factors in predicting outcome from the procedure</TI>
<SO>Clinical Experimental Dermatology</SO>
<YR>1988</YR>
<VL>13</VL>
<NO>1</NO>
<PG>4-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-1980" NAME="Henderson 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson HP, Marples RR, Richardson JF</AU>
<TI>Comparison of topical antibacterial agents in the preparation of varicose ulcers for skin grafting</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirsner-1997" NAME="Kirsner 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Kirsner RS, Eaglstein WH, Kerdel FA. Split-thickness skin grafting for lower extremity ulcerations. Dermatol-Surg 1997;23: 85-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirsner RS, Eaglstein WH, Kerdel FA</AU>
<TI>Split-thickness skin grafting for lower extremity ulcerations</TI>
<SO>Dermatologic Surgery</SO>
<YR>1997</YR>
<VL>23</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leigh-1986" NAME="Leigh 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Leigh IM, Purkis PE. Culture grafted leg ulcers. Clin Exp Dermatol. 1986 Nov; 11(6): 650-2&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leigh IM, Purkis PE</AU>
<TI>Culture grafted leg ulcers</TI>
<SO>Clinical Experimental Dermatology</SO>
<YR>1986</YR>
<VL>11</VL>
<NO>6</NO>
<PG>650-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Limova-1995" MODIFIED="2009-08-21 13:47:48 +0100" MODIFIED_BY="[Empty name]" NAME="Limova 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-21 13:47:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Limova M, Mauro T. Treatment of leg ulcers with cultured epithelial autografts: clinical study and case reports. Ostomy Wound Management 1995; 41(8), 48-50, 52, 54-60.&lt;/p&gt;" NOTES_MODIFIED="2009-08-21 13:47:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limova M, Mauro T</AU>
<TI>Treatment of leg ulcers with cultured epithelial autografts: clinical study and case reports</TI>
<SO>Ostomy/Wound Management</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>8</NO>
<PG>48-50, 52, 54-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahajan-1995" NAME="Mahajan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Mahajan R, Mosley JG. Use of a semipermeable polyamide dressing over skin grafts to venous leg ulcers. 82. 1995:1359-60. (dressing/skin grafting polyamide monofilament woven mesh vs paraffin gauze and non-adherent dressings; Full; HS).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahajan R, Mosley JG</AU>
<TI>Use of a semipermeable polyamide dressing over skin grafts to venous leg ulcers</TI>
<SO>British Journal of Surgery</SO>
<YR>1995</YR>
<VL>82</VL>
<NO>10</NO>
<PG>1359-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcusson-1992" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Marcusson 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Marcusson JA, Lindgren C, Berghard A, Toftgard R. Allogeneic cultured keratinocytes in the treatment of leg ulcers. A pilot study. Acta Derm Venereol. 1992; 72(1): 61-4&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcusson JA, Lindgren C, Berghard A, Toftgard R</AU>
<TI>Allogeneic cultured keratinocytes in the treatment of leg ulcers: a pilot study</TI>
<SO>Acta Dermatologica Venereologica</SO>
<YR>1992</YR>
<VL>72</VL>
<NO>1</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mekkes-1992" NAME="Mekkes 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mekkes JR, Westerhof W</AU>
<TI>Excising necrotic venous ulcers, by using absorbing polysaccharide pads</TI>
<TO>Debridement van necrotische veneuze ulcera met behulp van absorberende polysaccharide pads</TO>
<SO>Therapie, Geneesmiddel en Onderzoek</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>9</NO>
<PG>253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millard-1977" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Millard 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Millard LG, Roberts MM, Gatecliffe M. Chronic leg ulcers treated by the pinch graft method. Br J Dermatol. 1977 Sep; 97(3): 289-95&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millard LG, Roberts MM, Gatecliffe M</AU>
<TI>Chronic leg ulcers treated by the pinch graft method</TI>
<SO>British Journal of Dermatology</SO>
<YR>1977</YR>
<VL>97</VL>
<NO>3</NO>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mol-1991" MODIFIED="2011-09-19 19:43:57 +0100" MODIFIED_BY="[Empty name]" NAME="Mol 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-09-19 19:43:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mol M, Nanninga B, Eendenburg J, Westerhof W, Mekkes J, Ginkel C</AU>
<TI>Grafting of venous leg ulcers</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1991</YR>
<VL>24</VL>
<NO>1</NO>
<PG>77-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mostow-2005" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Mostow 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mostow E, Haraway G, Dalsing M, Hodde J, King D</AU>
<TI>Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>5</NO>
<PG>837-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muhart-1998" MODIFIED="2011-10-27 17:07:59 +0100" MODIFIED_BY="[Empty name]" NAME="Muhart 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-10-27 17:07:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muhart M, McFalls S, Kirsner R, Kerdel F, Eaglstein WH</AU>
<TI>Bioengineered skin</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>350</VL>
<PG>1142</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donnell-2006" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="O'Donnell 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell Jr TF, Lau J</AU>
<TI>A systematic review of randomized controlled trials of wound dressings for chronic venous ulcers</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>5</NO>
<PG>1118-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oien-1998" NAME="Oien 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oien R, Hansen B, Hakansson A</AU>
<TI>Pinch grafting of leg ulcers in primary care</TI>
<SO>Acta Dermatologica Venereologica (Stockholm)</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>438-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega-2010" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortega Z, Hunziker T, Lauchi S, Mayer DO, Huber C, Baumann C, et al</AU>
<TI>Epidex Swiss field trial. 2004-2008</TI>
<SO>Dermatology</SO>
<YR>2010</YR>
<VL>221</VL>
<NO>4</NO>
<PG>365-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-1991a" NAME="Phillips 1991a" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Phillips TJ, Kehinde O, Green H, Gilchrest BA. Treatment of skin ulcers with cultured epidermal allografts. J Am Acad Dermatol. 1989 Aug; 21(2 Pt 1): 191-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips TJ, Kehinde O, Green H, Gilchrest BA</AU>
<TI>Treatment of skin ulcers with cultured epidermal allografts</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>2 Pt 1</NO>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-1991b" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Phillips 1991b" YEAR="1991">
<REFERENCE MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Phillips TJ. Cultured epidermal allografts -a temporary or permanent solution? Transplantation. 1991 May; 51(5): 937-41&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 16:12:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips TJ</AU>
<TI>Cultured epidermal allografts - a temporary or permanent solution?</TI>
<SO>Transplantation</SO>
<YR>1991</YR>
<VL>51</VL>
<NO>5</NO>
<PG>937-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pojda-1994" MODIFIED="2012-03-29 10:25:02 +0100" MODIFIED_BY="[Empty name]" NAME="Pojda 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-03-29 10:25:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pojda Z, Struzyna J</AU>
<TI>New method for treatment of the non-healing wounds with the split thickness skin grafts preincubated with granulocyte-macrophage colony-stimulating factor (GM-CSF)</TI>
<SO>4th Annual Meeting of the European Tissue Repair Society; 1994, 25-28 August; Oxford, England</SO>
<YR>1994</YR>
<PG>201</PG>
<ED>Lundblad WJ</ED>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puonti-1998" NAME="Puonti 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Puonti H, Asko Seljavaara S. Excision and skin grafting of leg ulcers. Ann Chir Gynaecol. 1998; 87(3): 219-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puonti H, Asko Seljavaara S</AU>
<TI>Excision and skin grafting of leg ulcers</TI>
<SO>Annales Chirurgiae Gynaecologiae</SO>
<YR>1998</YR>
<VL>87</VL>
<NO>3</NO>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruffieux-1997" NAME="Ruffieux 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ruffieux P, Hommel L, Saurat JH. Long-term assessment of chronic leg ulcer treatment by autologous skin grafts.Dermatology 1997; 195(1): 77-80&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruffieux P, Hommel L, Saurat JH</AU>
<TI>Long-term assessment of chronic leg ulcer treatment by autologous skin grafts</TI>
<SO>Dermatology</SO>
<YR>1997</YR>
<VL>195</VL>
<NO>1</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shehade-1989" NAME="Shehade 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shehade S, Clancy J, Blight A, Young K, Levick P</AU>
<TI>Cultured epithelial allografting of leg ulcers</TI>
<SO>Journal of Dermatological Treatment</SO>
<YR>1989</YR>
<VL>1/2</VL>
<PG>79-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skene-1992" NAME="Skene 1992" YEAR="">
<REFERENCE NOTES="&lt;p&gt;22. Skene AI, Smith JM, Dore CJ, Charlett A, Lewis JD . Venous leg ulcers: a prognostic index to predict time to healing. 305. 1992:1119-21. (compression/stockings two layers of shaped tubigrip vs a Venosan stocking; Full.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skene AI, Smith JM, Dore CJ, Charlett A, Lewis JD</AU>
<TI>Venous leg ulcers: a prognostic index to predict time to healing</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>305</VL>
<NO>6862</NO>
<PG>1119-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slonkova-2002" MODIFIED="2009-11-06 12:19:14 +0000" MODIFIED_BY="[Empty name]" NAME="Slonkova 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-06 12:19:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slonkova V, Navratilova Z, Semradova V, Adler J</AU>
<TI>Cultures epidermal keratinocytes in the treatment of leg ulcers. Part 11. Comparison of the effect of cryopreserved and lyophilized allografts</TI>
<SO>Cesko-Slovenska Dermatologie</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>6</NO>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steele-1985" NAME="Steele 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Steele K. Pinch grafting for chronic venous leg ulcers in general practice. J R Coll Gen Pract. 1985 Dec; 35(281): 574-5&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steele K</AU>
<TI>Pinch grafting for chronic venous leg ulcers in general practice</TI>
<SO>Journal of the Royal College of General Practitioners</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>281</NO>
<PG>574-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Townsend-1970" MODIFIED="2011-10-27 17:09:19 +0100" MODIFIED_BY="[Empty name]" NAME="Townsend 1970" YEAR="1970">
<REFERENCE MODIFIED="2011-10-27 17:09:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Townsend J. Skin grafting leg ulcers. Lancet 1970 Jan 3; 1(7636): 39.&lt;/p&gt;" NOTES_MODIFIED="2011-10-27 17:09:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Townsend J</AU>
<TI>Skin grafting leg ulcers</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>1</VL>
<NO>7636</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trent-1998" NAME="Trent 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Trent JF, Kirsner RS. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. Int J Clin Pract. 1998 Sep; 52(6): 408-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trent JF, Kirsner RS</AU>
<TI>Tissue engineered skin: Apligraf, a bi-layered living skin equivalent</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>6</NO>
<PG>408-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-den-Hoogenband-1984" MODIFIED="2011-10-27 17:10:09 +0100" MODIFIED_BY="[Empty name]" NAME="Van den Hoogenband 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;van den Hoogenband HM. Treatment of leg ulcers with split-thickness skin grafts. J Dermatol Surg Oncol. 1984 Aug; 10(8): 605-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Hoogenband HM</AU>
<TI>Treatment of leg ulcers with split-thickness skin grafts</TI>
<SO>Journal of Dermatology, Surgery and Oncology</SO>
<YR>1984</YR>
<VL>10</VL>
<NO>8</NO>
<PG>605-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villeneuve-1998" NAME="Villeneuve 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Villeneuve P, Hafner J, Prenosil JE, Elsner P, Burg G. A novel culturing and grafting system for the treatment of leg ulcers. British Journal of Dermatology 1998 May; 138(5): 849-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villeneuve P, Hafner J, Prenosil JE, Elsner P, Burg G</AU>
<TI>A novel culturing and grafting system for the treatment of leg ulcers</TI>
<SO>British Journal of Dermatology</SO>
<YR>1998</YR>
<VL>138</VL>
<NO>5</NO>
<PG>849-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vin-2002" MODIFIED="2011-10-27 17:09:44 +0100" MODIFIED_BY="[Empty name]" NAME="Vin 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-27 17:09:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vin F, Teot L, Meaume S</AU>
<TI>The healing properties of Promogran in venous leg ulcers</TI>
<SO>Journal of Wound Care</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>9</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-1989" NAME="Ward 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Ward DJ, Bennett JP, Burgos H, Fabre J. The healing of chronic venous leg ulcers with prepared human amnion. 42. 1989:463-7. (topical agent amnion: fresh vs frozen vs lyophilised vs tissue cultured maintained; Full.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward DJ, Bennett JP, Burgos H, Fabre J</AU>
<TI>The healing of chronic venous leg ulcers with prepared human amnion</TI>
<SO>British Journal of Plastic Surgery</SO>
<YR>1989</YR>
<VL>42</VL>
<NO>4</NO>
<PG>463-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-03-29 11:13:54 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Wille-2011" MODIFIED="2011-10-28 12:04:27 +0100" MODIFIED_BY="[Empty name]" NAME="Wille 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-10-28 12:04:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wille JJ, Burdge JJ, Pitttelkow MR</AU>
<TI>Rapid healing of chronic venous stasis leg ulcers treated by the application of a novel serum-free cultured autologous epidermis</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2011</YR>
<VL>19</VL>
<NO>4</NO>
<PG>464-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-03-29 11:20:05 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-03-29 11:20:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Apligraf-2010" MODIFIED="2012-03-29 11:17:28 +0100" MODIFIED_BY="[Empty name]" NAME="Apligraf 2010" TYPE="OTHER">
<AU>Organogenesis</AU>
<TI>Apligraf: add life after healing</TI>
<SO>http://www.apligraf.com/</SO>
<YR>2010</YR>
<PB>Organogenesis Inc.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baker-1992" MODIFIED="2008-10-29 14:16:19 +0000" MODIFIED_BY="[Empty name]" NAME="Baker 1992" TYPE="JOURNAL_ARTICLE">
<AU>Baker SR, Stacey MC, Singh G, Hoskin SE, Thompson PJ</AU>
<TI>Aetiology of chronic leg ulcers</TI>
<SO>European Journal of Vascular Surgery</SO>
<YR>1992</YR>
<VL>6</VL>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barrandon-1987" NAME="Barrandon 1987" TYPE="JOURNAL_ARTICLE">
<AU>Barrandon Y, Green G</AU>
<TI>Three clonal type keratinocytes with different capacities for multiplication</TI>
<SO>Proceedings of the National Academy of Science (USA)</SO>
<YR>1987</YR>
<VL>84</VL>
<PG>2302-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barwell-2004" MODIFIED="2011-11-01 16:12:47 +0000" MODIFIED_BY="[Empty name]" NAME="Barwell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Barwell JR, Davies CE, Deacon J, Harvey K, Minor J, Sassano A, et al</AU>
<TI>Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>1854-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosanquet-1992" MODIFIED="2008-10-29 14:16:25 +0000" MODIFIED_BY="[Empty name]" NAME="Bosanquet 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bosanquet N</AU>
<TI>Costs of venous ulcers - from maintenance therapy to investment programs</TI>
<SO>Phlebology</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>44-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callam-1985" MODIFIED="2012-03-29 11:18:53 +0100" MODIFIED_BY="[Empty name]" NAME="Callam 1985" TYPE="JOURNAL_ARTICLE">
<AU>Callam MJ, Ruckley CV, Harper DR, Dale JJ</AU>
<TI>Chronic ulceration of the leg: extent of the problem and the provision of care</TI>
<SO>British Medical Journal</SO>
<YR>1985</YR>
<VL>290</VL>
<NO>6485</NO>
<PG>1855-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callam-1989" MODIFIED="2008-10-29 14:16:34 +0000" MODIFIED_BY="[Empty name]" NAME="Callam 1989" TYPE="BOOK">
<AU>Callam MJ</AU>
<SO>Chronic leg ulceration: the Lothian and Forth Valley Leg Ulcer Study</SO>
<YR>1989</YR>
<PB>ChM Thesis</PB>
<CY>University of Dundee</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Charles-1995" MODIFIED="2008-10-29 14:16:46 +0000" MODIFIED_BY="[Empty name]" NAME="Charles 1995" TYPE="JOURNAL_ARTICLE">
<AU>Charles H</AU>
<TI>The impact of leg ulcers on patients' quality of life</TI>
<SO>Professional Nurse</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>571-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Compton-1995" NAME="Compton 1995" TYPE="JOURNAL_ARTICLE">
<AU>Compton CC, Tong Y, Trookman N, Zhao H, Roy D, Press W</AU>
<TI>Transforming growth factor and gene expression in cultured human keratinocytes is unaffected by cellular ageing</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<PG>683-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enoch-2005" MODIFIED="2009-08-21 13:53:21 +0100" MODIFIED_BY="[Empty name]" NAME="Enoch 2005" TYPE="JOURNAL_ARTICLE">
<AU>Enoch S, Shaaban H, Dunn KW</AU>
<TI>Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material</TI>
<SO>Journal of Medical Ethics</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-03-29 11:19:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-09-19 19:53:17 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (Editors)</AU>
<TI>Chapter 8. Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lees-1992" MODIFIED="2008-10-29 14:16:54 +0000" MODIFIED_BY="[Empty name]" NAME="Lees 1992" TYPE="JOURNAL_ARTICLE">
<AU>Lees TA, Lambert D</AU>
<TI>Prevalence of lower limb ulceration in an urban health district</TI>
<SO>British Journal of Surgery</SO>
<YR>1992</YR>
<VL>79</VL>
<PG>1032-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-10-28 12:06:07 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Margolis-2004" MODIFIED="2012-03-29 11:19:40 +0100" MODIFIED_BY="[Empty name]" NAME="Margolis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA</AU>
<TI>The accuracy of venous leg ulcer prognostic models in a wound care system</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>2</NO>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phillips-1989" MODIFIED="2012-03-29 11:20:05 +0100" MODIFIED_BY="[Empty name]" NAME="Phillips 1989" TYPE="JOURNAL_ARTICLE">
<AU>Phillips T, Kehinde O, Green H, Gilchrest BA</AU>
<TI>Treatment of skin ulcers with cultured epidermal allografts</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>2 Pt 1</NO>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2011" MODIFIED="2012-03-28 17:13:14 +0100" MODIFIED_BY="[Empty name]" NAME="SIGN 2011" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Search filters</TI>
<SO>http://www.sign.ac.uk/methodology/filters.html#random</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-10-29 14:17:56 +0000" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-11-30 09:47:49 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-11-30 09:47:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-01 16:03:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown_x002d_Etris-2000">
<CHAR_METHODS MODIFIED="2011-11-01 16:03:10 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 6-month follow-up. Method of randomisation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:03:14 +0000" MODIFIED_BY="[Empty name]">
<P>36 patients from 8 centres. Only people with "hard to heal ulcers" included.<BR/>Exclusion criteria: people whose ulcers had reduced in area by &gt; 30% over 2 weeks with standard care<BR/>Inclusion criteria: people with "hard to heal" venous ulcers<BR/>Median size of ulcers:<BR/>Group 1: = 4.5 cm²; Group 2: = 4.5 cm²<BR/>Median duration of ulcers:<BR/>Group 1: = 9 months; Group 2: = 10 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:03:15 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: allogenic bilaminar Composite Cultured Skin (CCS: OrCel (trademark)), plus foam dressing and compression (CCS given as a single application each week for up to 4 weeks)<BR/>Group 2: standard care, i.e. absorptive foam dressing and compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:03:17 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers of participants totally healed at 6 months:<BR/>Group 1: = 71%; Group 2: = 37%<BR/>(Probable that Group 1 had 12/17 healed and Group 2: had 7/19 healed)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:03:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burdge-2000">
<CHAR_METHODS MODIFIED="2011-11-01 16:03:25 +0000" MODIFIED_BY="[Empty name]">
<P>RCT (allocated in 2:1 ratio)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:03:29 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: people with venous leg ulcers diagnosed by venous Duplex scan; min duration 1 month; age 18 or over; ulcer area at least 6 cm²; ulcer at least stage II or III as defined by IAET ulcer score; life expectancy of at least 12 months; Karnofsky score of at least 50 (0 to 100 scale that measures a person's ability to perform common tasks); BMI between 19 and 36<BR/>Exclusion criteria: immuno-compromised patients; pregnancy/lactation; received chemotherapy within 30 days; history of irradiation of the ulcer area; uncontrolled diabetes; exposed bone, tendon, or fascia; osteomyelitis; active vasculitis; receiving haemodialysis; received corticosteroids &gt;15 mg/d in last 30 days; ABPI &lt; 0.65<BR/>Patient age in years:<BR/>Group 1: = 62 (SEM 6); Group 2: = 64 (SEM 9)<BR/>Wound duration in months:<BR/>Group 1: = 25 (SEM 8); Group 2: = 32 (SEM 16)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:03:31 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 10) cultured epidermal autograft (Autoderm - trademark) (Compression bandages applied for 7 to 21 days (graft is harvested and grown during this time), then autograft applied on backing of tulle gras, weekly for 8 weeks)<BR/>Group 2: (n = 5) standard care (debridement and compression)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:03:32 +0000" MODIFIED_BY="[Empty name]">
<P>Number of ulcers healed completely at 12 weeks:<BR/>Group 1: = 8/10 (80%)<BR/>Group 2: = 1/5 (20%)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-02 19:17:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duhra-1992">
<CHAR_METHODS MODIFIED="2011-11-01 16:03:43 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 6 weeks' follow-up<BR/>Method of randomisation unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:03:45 +0000" MODIFIED_BY="[Empty name]">
<P>22 participants with 30 ulcers treated in outpatients department<BR/>Groups matched at baseline for age, sex, mean ulcer area and ulcer duration<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-02 19:17:33 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 15) allograft (cultured keratinocytes placed on a N-A dressing)<BR/>Group 2: (n = 15) placebo (NA dressing soaked in culture medium)<BR/>All participants received paraffin ointment impregnated tulle, gauze, absorbent pad, tubular elasticated bandage and compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:03:50 +0000" MODIFIED_BY="[Empty name]">
<P>Healing rate over 6 weeks:<BR/>a) Numbers healed at 6 weeks:<BR/>Group 1: = 1/15<BR/>Group 2: = 0/15<BR/>b) Reduction in ulcer area (mean and SE): presented as a graph only in paper<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:04:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Falanga-1998">
<CHAR_METHODS MODIFIED="2011-11-01 16:04:07 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 8 weeks' treatment and a 6-month follow-up<BR/>Method of randomisation: used computer-generated randomisation schedules<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:04:08 +0000" MODIFIED_BY="[Empty name]">
<P>309 participants randomised with 293 treated as outpatients in 15 centres<BR/>Groups well matched at baseline for age, sex, mean ulcer area and ulcer duration<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:04:09 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 146) human skin equivalent and compression<BR/>Group 2: (n = 129) dressing (made to look the same as intervention) and compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:04:12 +0000" MODIFIED_BY="[Empty name]">
<P>a) Incidence of complete healing by 6 months:<BR/>Group 1: = 92/146<BR/>Group 2: = 63/129<BR/>b) Time required for complete healing to occur (days):<BR/>Group 1: = 61 days (range 9 to 233 days)<BR/>Group 2: = 181 days (range 10 to 232 days)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:04:14 +0000" MODIFIED_BY="[Empty name]">
<P>Authors stated result as number of participants available for final analysis rather than number randomised, i.e. not an intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:04:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goedkoop-2010">
<CHAR_METHODS MODIFIED="2011-11-01 16:04:24 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind and placebo-controlled RCT with up to 24-week follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:04:25 +0000" MODIFIED_BY="[Empty name]">
<P>110 participants</P>
<P>Inpatient and outpatients settings</P>
<P>The groups were matched at baseline for important variables such as duration of ulcer and ulcer size</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:04:38 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 15) control receiving placebo (vials containing the spray without the cells)</P>
<P>Intervention groups listed below varied in the ratio of keratinocytes (K) to fibroblasts (F) and in the concentration of cells (x 10<SUP>6</SUP> cells/ml)</P>
<P>Group 2: (n = 14) received intervention at K/F ratio 1:9, concentration 2.5</P>
<P>Group 3: (n = 17) received intervention at K/F ratio 1:9, concentration 5</P>
<P>Group 4: (n = 15) received intervention at K/F ratio 1:9, concentration 10</P>
<P>Group 5: (n = 17) received intervention at K/F ratio 1:1, concentration 2.5</P>
<P>Group 6: (n = 16) received intervention at K/F ratio 1:1, concentration 5</P>
<P>Group 7: (n = 16) received intervention at K/F ratio 1:1, concentration 10</P>
<P>The results comprised pooling into 2 intervention groups according to the K/F ratio</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:04:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Percentage of ulcers completely healed at 12 weeks:</B>
</P>
<P>Group 1: 38% 3/8<BR/>Groups 2 to 4 (pooled): 47% 15/32</P>
<P>Groups 5 to 7 (pooled): 47% 16/34</P>
<P>
<B>Percentage of ulcers completely healed at 24 weeks:</B>
</P>
<P>Group 1: 50% 4/8</P>
<P>Groups 2 to 4 (pooled): 66% 21/32</P>
<P>Groups 5 to 7 (pooled): 56% 19/34</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:04:45 +0000" MODIFIED_BY="[Empty name]">
<P>Group 3 displayed the highest levels of ulcer healing and the most favourable primary outcome findings (a combination of K:F of 1:9 and concentration 5 x 10<SUP>6</SUP> cells)  </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:05:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jankunas-2007">
<CHAR_METHODS MODIFIED="2011-11-01 16:04:57 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 6-month follow-up. Method of randomisation: card picked by nurse</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-06 12:04:50 +0000" MODIFIED_BY="[Empty name]">
<P>71 people treated as either inpatients or outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:04:59 +0000" MODIFIED_BY="[Empty name]">
<P>Rate of complete healing by 6 months<BR/>Group 1: surgical skin autograft<BR/>Group 2: hydrocolloid dressing<BR/>All received compression therapy throughout</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:04:59 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: = 27/40<BR/>Group 2: = 0/31</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:05:00 +0000" MODIFIED_BY="[Empty name]">
<P>Ulcers in the surgical group 1 were larger and older with patients remaining in hospital for 10.7 days compared to 10.3 days for the control group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:05:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krishnamoorthy-2003">
<CHAR_METHODS MODIFIED="2011-11-01 16:05:17 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 12-week follow-up. RCT with 12-week follow-up. Method of randomisation: sealed envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:05:17 +0000" MODIFIED_BY="[Empty name]">
<P>53 people from 6 centres in UK and Canada treated in outpatients departments</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:05:20 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Dermagraft, weekly for 11 weeks (total of 12 applications)<BR/>Group 2: Dermagraft at 0, 1, 4 and 8 weeks (4 applications)<BR/>Group 3: Dermagraft at time 0 (1 application)<BR/>Group 4: no Dermagraft<BR/>All received 4-layer compression bandaging throughout<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:05:23 +0000" MODIFIED_BY="[Empty name]">
<P>Incidence of complete healing by 12 weeks:<BR/>Group 1: = 5/13<BR/>Group 2: = 5/13<BR/>Group 3: = 1/14<BR/>Group 4: = 2/13<BR/>Percentage reduction in ulcer area:<BR/>Group 1: = 81.4<BR/>Group 2: = 88.6<BR/>Group 3: = 59.4<BR/>Group 4: = 78.1<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Ulcers in the control group were larger and older. Median area of control group was 31% larger than the total group average. Median duration was also 54% longer than total group average.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:05:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindgren-1998">
<CHAR_METHODS MODIFIED="2009-11-06 14:49:12 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 8 weeks' treatment. Method of randomisation: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:05:32 +0000" MODIFIED_BY="[Empty name]">
<P>27 participants with venous ulcers treated in outpatient department<BR/>Groups matched at baseline for age, sex, ulcer duration and mean ulcer area<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:05:33 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 15) cryopreserved allografts, dressing (Mepitel) and compression<BR/>Group 2: (n = 12) dressing (Mepitel) and compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:05:34 +0000" MODIFIED_BY="[Empty name]">
<P>a) Number with ulcer healed at 8 weeks:<BR/>Group 1: = 2/15<BR/>Group 2: = 2/12<BR/>b) Number with a reduction in ulcer area:<BR/>Group 1: = 8/15<BR/>Group 2: = 6/12<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:05:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004">
<CHAR_METHODS MODIFIED="2011-11-01 16:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>12-week follow-up. Randomisation schedule was computer-generated, but not clear if allocation was concealed.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:05:48 +0000" MODIFIED_BY="[Empty name]">
<P>10 people with ulcers of at least 3 months' duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:05:48 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 5) single dose of autograft of keratinocytes cultured on porcine gelatin microbeads<BR/>Group 2: (n = 5) single dose of autograft of keratinocytes cultured on porcine collagen pads<BR/>Ulcers in both groups were surgically cleansed and debrided under local anaesthetic. A non-adherent, antibiotic impregnated tulle was used to cover graft, with a cotton gauze. Both groups had an elastic multilayer-bandage wrap. Dressings were changed 3 days after transplantation and daily thereafter.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:05:51 +0000" MODIFIED_BY="[Empty name]">
<P>Healed by 12 weeks:<BR/>Group 1: = 1/4<BR/>Group 2: = 1/4<BR/>Reduction in area:<BR/>Group 1: = 83%<BR/>Group 2: = 50%<BR/>Adverse effects: none in either group<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:05:51 +0000" MODIFIED_BY="[Empty name]">
<P>Study reports on 15 people: after recruitment of 10 patients (randomised trial) 5 people were treated with multiple doses of keratinocytes on porcine gelatin microbeads</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:06:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navratilova-2004">
<CHAR_METHODS MODIFIED="2011-11-01 16:05:59 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 3 months' follow-up. Method of randomisation: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:06:03 +0000" MODIFIED_BY="[Empty name]">
<P>50 hospitalised participants (18 male)<BR/>Ulcer area at baseline:<BR/>Group 1: = 12.41 cm²<BR/>Group 2: = 9.04 cm²<BR/>Mean duration at baseline:<BR/>Group 1: = 30.7 months<BR/>Group 2: = 16.7 months<BR/>Inclusion criteria: ulcer larger than 2 cm² and of at least 3 months' duration<BR/>Exclusion criteria: arterial ulcer; uncompensated diabetes; pronounced anaemia; uncompensated heart insufficiency; pronounced hypoproteinaemia; ABPI &lt; 0.8; metastatic malignant tumour; systemic immunosuppressive therapy<BR/>Mean age 63 years<BR/>Mean BMI 30.1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:06:06 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 25) cryopreserved cultured epidermal keratinocytes (allograft)<BR/>Group 2: (n = 25) lyophilised cultured epidermal keratinocytes (allograft)<BR/>Allografts applied when ulcer bed had a granulating base. Graft dressings covered with nonadherent silicone dressing, layers of dry gauze, a gauze bandage and a low-strength sterile bandage. Patients were advised to rest in bed for 48 hours after grafting.<BR/>Dressings removed at 5 days, then replaced at 3-day intervals<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:06:06 +0000" MODIFIED_BY="[Empty name]">
<P>Number with a healed ulcer at 90 days:<BR/>Group 1: = 21/25<BR/>Group 2: = 20/25<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:06:07 +0000" MODIFIED_BY="[Empty name]">
<P>Figure shows pain reducing over duration of trial but no detailed data provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:06:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Omar-2004">
<CHAR_METHODS MODIFIED="2011-11-01 16:06:14 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 12 weeks' follow-up. Method of randomisation: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:06:17 +0000" MODIFIED_BY="[Empty name]">
<P>18 people with ulcers &gt; 12 weeks' duration<BR/>Inclusion criteria: clean ulcers with healthy granulation tissue; duplex finding of venous dysfunction; ABPI &gt; 0.9<BR/>Mean ulcer duration at baseline:<BR/>Group 1: = 118.8 weeks<BR/>Group 2: = 120 weeks<BR/>Mean ulcer area at baseline:<BR/>Group 1: = 9.5 cm² (SD 4.2)<BR/>Group 2: = 12.3 cm² (SD 7.6)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:06:18 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 10) human fibroblast-derived dermal replacement (Dermagraft - trademark)<BR/>Group 2: (n = 8) non-adherent dressing<BR/>All patients received high compression, 4-layer bandaging<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:06:20 +0000" MODIFIED_BY="[Empty name]">
<P>Number healed at week 12:<BR/>Group 1: = 5/10<BR/>Group 2: = 1/8<BR/>Reduction in area over trial in cm² per week:<BR/>Group 1: = 0.82 (SD 0.33)<BR/>Group 2: = 0.15 (SD 0.39)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:06:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paquet-2005">
<CHAR_METHODS MODIFIED="2011-11-01 16:06:30 +0000" MODIFIED_BY="[Empty name]">
<P>Split-ulcer RCT with 8 weeks' follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:06:30 +0000" MODIFIED_BY="[Empty name]">
<P>4 women with venous ulcers of min 3 months' duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:06:32 +0000" MODIFIED_BY="[Empty name]">
<P>2-week run-in period of dressings and cleansing<BR/>Group 1: half of ulcer (proximal or distal) had cultured allogenic keratinocyte dressing (1 had fresh, 3 had frozen)<BR/>Group 2: half of ulcer (proximal or distal) had petrolatum gauze dressing<BR/>Leg was wrapped with a Rosidal bandage<BR/>Treatment reapplied weekly for 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:06:33 +0000" MODIFIED_BY="[Empty name]">
<P>Reduction in area divided by initial perimeter:<BR/>Group 1: = +1 mm (SD 6.2)<BR/>Group 2: = -0.55 mm (SD 3.9) (an increase in area)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:06:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poskitt-1987">
<CHAR_METHODS MODIFIED="2011-11-01 16:06:40 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 12 weeks' follow-up. Allocation using random number tables to generate sealed envelopes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:06:41 +0000" MODIFIED_BY="[Empty name]">
<P>51 participants with 53 venous ulcers<BR/>Inpatient and outpatient settings used<BR/>Groups well matched at baseline for important variables such as mean ulcer area, duration of ulcer and age of participants<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:06:42 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 25) pinch grafts and compression<BR/>Group 2: (n = 28) porcine dermis (a xenograft) and compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>a) Number with ulcer healed at 6 weeks:<BR/>Group 1: = 16/25<BR/>Group 2: = 8/28<BR/>b) Number with ulcer healed at 12 weeks:<BR/>Group 1: = 18/25<BR/>Group 2: = 13/28<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:06:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salomon-2002">
<CHAR_METHODS MODIFIED="2011-11-01 16:06:52 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 12 weeks' follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-19 15:15:14 +0100" MODIFIED_BY="[Empty name]">
<P>92 randomised. The analysis presented data on 77 patients but data available for 92 (a total of 13 in the meshed graft group dropped out and 2 in the Epidex group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:06:53 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: Epidex an autologous epidermal equivalent grown form keratinocytes of hair follicles<BR/>Group 2: meshed skin autograft</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:06:56 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: 14/45<BR/>Group 2: 14/47<BR/>Healed at week 12 - ITT analysis undertaken - all patients for whom the data were not presented at follow-up were assumed to be treatment failures<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:06:57 +0000" MODIFIED_BY="[Empty name]">
<P>This report was available only as a conference abstract; we wrote to the author to request further information but received no reply</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:07:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tausche-2003">
<CHAR_METHODS MODIFIED="2011-11-01 16:07:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 6 months' follow-up. Allocation blinded to patients and investigators until 1 week prior to treatment.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>99 people enrolled and 92 randomised. The analysis presented data on 77 who received treatment as randomised (15 dropped out between randomisation and treatment: 2 from Group 1, and 13 from Group 2).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:07:06 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: autologous epidermal equivalents derived from hair follicles captured from plucked hairs (50 to 200 per patient)<BR/>Group 2: meshed skin autograft<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:07:07 +0000" MODIFIED_BY="[Empty name]">
<P>People with ulcers healed at 6 months:<BR/>Group 1: = 19/45<BR/>Group 2: = 16/47<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:07:07 +0000" MODIFIED_BY="[Empty name]">
<P>2 patients in Group 1 were excluded after randomisation compared with 13 patients in Group 2 (of whom 8 refused the surgery)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:07:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teepe-1993">
<CHAR_METHODS MODIFIED="2011-11-01 16:07:15 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 12 weeks' follow-up. Method of randomisation not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:07:16 +0000" MODIFIED_BY="[Empty name]">
<P>43 participants with 47 ulcers treated in 2 outpatient departments<BR/>Groups matched at baseline for ulcer area, ulcer duration, age and sex<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:07:17 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: cryopreserved allografts<BR/>Group 2: hydrocolloid dressing<BR/>Both groups received short stretch bandages<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:07:19 +0000" MODIFIED_BY="[Empty name]">
<P>a) Number with ulcer healed at 6 weeks:<BR/>Group 1: = 6/24<BR/>Group 2: = 5/23<BR/>b) Number with ulcer healed at 12 weeks: not relevant as cross-over at 6 weeks<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-01 16:07:19 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-01 16:07:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warburg-1994">
<CHAR_METHODS MODIFIED="2011-11-01 16:07:32 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with 12 months' follow-up. Method of allocation: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-01 16:07:40 +0000" MODIFIED_BY="[Empty name]">
<P>31 participants with venous leg ulcers, treated as inpatients and outpatients (3-arm trial - 3rd arm of 16 people not relevant to this review)<BR/>Groups appeared to be well matched at baseline for age and sex. Not well matched for ulcer duration or baseline ulcer area.<BR/>Median area (range):<BR/>Group 1: = 7 cm² (1.1 to 347 cm²)<BR/>Group 2: = 41.2 cm² (2.1 to 290 cm²)<BR/>Median duration (range):<BR/>Group 1: = 24 months (1 to 72 months)<BR/>Group 2: = 18 months (3 to 72 months)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-01 16:07:41 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: (n = 16) meshed split-skin graft and surgery with compression<BR/>Group 2: (n = 15) surgery for incompetent perforators and compression<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-01 16:07:47 +0000" MODIFIED_BY="[Empty name]">
<P>Number healed at 12 months:<BR/>Group 1: = 5/15<BR/>Group 2: = 6/16<BR/>Time to complete healing:<BR/>Group 1: = 5.5 months (1.5 to 12 months)<BR/>Group 2: = 3 months (1 to 12 months)<BR/>Median ulcer area after 1 year:<BR/>Group 1: = 6.5 cm² (0-63)<BR/>Group 2: = 4.1 cm² (0-427)<BR/>(Not clear if figures in brackets are ranges)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations</P>
<P>&gt; = more than<BR/>&lt; = less than<BR/>ABPI = ankle brachial pressure index<BR/>BMI = body mass index<BR/>CCA = cryopreserved allografts<BR/>CEAP = a system to classify the severity, cause, site and specific abnormality of venous disease<BR/>d = day(s)<BR/>h = hour(s)<BR/>HCD = hydrocolloid<BR/>HSE = human skin equivalent<BR/>IAET = International Association Enterostomal Therapy (IAET) staging classification<BR/>ITT = intention-to-treat<BR/>LTF = loss to follow up<BR/>min = minimum<BR/>NA = not applicable<BR/>N-A = non-adherent<BR/>RCT: randomised controlled trial<BR/>SCC = squamous cell carcinoma<BR/>SD = standard deviation<BR/>SEM = standard error</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-11-01 16:08:27 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ahnlide-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Altman-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter describing use of Apligraf</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andersen-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beele-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berretty-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:53 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boyce-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:56 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calonge-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:57 +0000" MODIFIED_BY="[Empty name]">
<P>The trial compared autografts and allografts in 15 patients, but no data were provided on the healing rates for the 2 groups. Abstract only available presenting insufficient data, authors contacted for further information, but no response received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpentier-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:57 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carver-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:58 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-19 13:13:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-19 13:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diabetic foot ulceration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christiansen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:58 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:07:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clancy-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:07:59 +0000" MODIFIED_BY="[Empty name]">
<P>No information provided on how patients were allocated to the 2 groups (see also <LINK REF="STD-Shehade-1989" TYPE="STUDY">Shehade 1989</LINK> which may report the same trial in more detail)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coney-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dahlstrom-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention was fibrin adhesive applied to grafts or not, therefore evaluation was of the treatment of grafts not grafts per se</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demling-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>Not a graft but a dressing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fahey-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:01 +0000" MODIFIED_BY="[Empty name]">
<P>Description of use of skin graft</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farah-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:01 +0000" MODIFIED_BY="[Empty name]">
<P>A review article, not a trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halter-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:02 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:02 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrison-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:02 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henderson-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention was antibacterial agent to clean graft site prior to grafting. Evaluation was of graft site preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirsner-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:03 +0000" MODIFIED_BY="[Empty name]">
<P>Description of use of skin graft</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leigh-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:03 +0000" MODIFIED_BY="[Empty name]">
<P>Case study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Limova-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:03 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahajan-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:04 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcusson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:04 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mekkes-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluation was of graft site preparation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Millard-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mol-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mostow-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:06 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention is a freeze-dried dressing made of intestinal mucosa - so will be considered as a dressing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muhart-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:06 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluated treatment of skin graft donor sites</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Donnell-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:07 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oien-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:16 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:17 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phillips-1991a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:18 +0000" MODIFIED_BY="[Empty name]">
<P>Non-systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phillips-1991b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:18 +0000" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pojda-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:21 +0000" MODIFIED_BY="[Empty name]">
<P>Trial included only 1 person (out of 5 studied) with a venous ulcer. The study compared 3 methods of preparing split-thickness skin grafts, namely: the usual method; incubation in Iscoves medium, albumin and GM-CSF (a growth factor); and Iscoves medium and albumin alone. There was no information in this abstract about how the comparison was performed - was the ulcer divided into 3, or was each ulcer allocated to one form of graft? The authors were contacted for further information, but no response received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puonti-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:22 +0000" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruffieux-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:22 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shehade-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skene-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:23 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were 2 wound dressings</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Slonkova-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:24 +0000" MODIFIED_BY="[Empty name]">
<P>Czech translator, no evidence that it is a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steele-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:24 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Townsend-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:24 +0000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trent-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:25 +0000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-den-Hoogenband-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:25 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villeneuve-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:25 +0000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-01 16:08:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-01 16:08:26 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention was a collagen/oxidised regenerated cellulose dressing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ward-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention was amnion on graft site prior to grafting. Evaluation was of graft site preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-03-29 11:25:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-03-29 11:25:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wille-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-03-29 11:25:58 +0100" MODIFIED_BY="[Empty name]">
<P>Awaiting full text retrieval </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-07 13:59:32 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-01 16:07:20 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Quote: &#8220;The objective of this randomised, parallel group, feasibility study&#8230;&#8221;</P>
<P>Comment:<B> </B>no mention of method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:37:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Quote: "An IRB approved clinical protocol called for the random assignment of 5 patients to the control group and 10 patients to the autoderm treatment group&#8221;</P>
<P>Comment: no evidence of method of randomisation mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Quote: &#8220;The ulcers were randomly allocated to receive the allograft or placebo in a double blind fashion&#8221;</P>
<P>Comment: it appears unclear which method, if any, was used for randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Quote: &#8220;computer-generated randomisation schedules&#8221;</P>
<P>Comment: clear evidence of method of randomisation given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Quote: &#8220;All 118 were randomised to treatment&#8221;</P>
<P>Comment: method of generating the randomisation sequence is not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Quote: &#8220;a nurse working with the instigator, pulled out 1 or 2 cards that had either a + (surgery) or &#8211; (conservative)&#8221;</P>
<P>Comment: unclear description of method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Quote: &#8220;&#8230;computer generated scheme&#8221;</P>
<P>Comment: clear method of randomisation identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Quote: &#8220;&#8230;randomised to two groups&#8221;</P>
<P>Comment: randomisation mentioned however no method outlined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Quote: &#8220;computer generated randomization schedules&#8221;</P>
<P>Comment: evidence of adequate method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Quote: &#8220;The study was randomised (the patients were numbered in the order they entered the study)"</P>
<P>Comment: unclear whether the sequence was randomly generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:38:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Quote: "Protocol-eligible patients were prospectively randomised to treatment (Dermagraft) according to the computer generated code on order of admittance to the study"</P>
<P>Comment: clear method of randomisation identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:38:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Quote: &#8220;Four women aged 61-83 were enrolled&#8221;. &#8220;The randomised investigational products were applied&#8230;&#8221;</P>
<P>Comment: unclear whether the participants were randomised or the interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Quote: &#8220;random number tables&#8221;</P>
<P>Comment: randomisation achieved through random number tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Quote: &#8220;92 eligible patients&#8230;.were randomised to inpatient mesh graft or ambulatory epidex in 12 centres in Germany&#8221;</P>
<P>Comment: method or random sequence generation not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Quote: &#8220;&#8230;patients were randomised centrally to treatment&#8230;with a block size of 5&#8221;</P>
<P>Comment: the study reported using block randomisation to generate the sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Quote: &#8220;Both centres were randomised separately&#8221;. &#8220;For each six consecutive patients, three were randomised to CCA, and three to HCD&#8221;</P>
<P>Comment: although the method of allocation is present, the generation of the randomisation sequence is not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Quote: &#8220;After informed consent, patients were randomised into 3 groups&#8221;</P>
<P>Comment: method of generating the randomisation sequence is not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-01 16:07:47 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Comment: no evidence of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Quote: &#8220;Centrally randomised&#8221;</P>
<P>Comment: no reference to concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Quote: &#8220;sealed envelopes&#8221;</P>
<P>Comment: although sealed envelopes were used, no mention was made regarding whether the envelopes were opaque and sequentially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Quote: "For each consecutive 6 patients, three were randomised to CCA and 3 to HCD&#8221;</P>
<P>Comment: allocation was not concealed as alternation was used to allocate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-07-07 14:03:18 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-01 16:07:48 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:03:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Comment: no data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:03:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:03:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Comment: all randomised participants accounted for in the final analysis. N = 30. Therefore ITT assumed to be used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:04:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Quote: &#8220;309 were randomised for the trial and 293 were treated; for final statistical analysis 275 patients who met inclusion/exclusion criteria were evaluated&#8221;</P>
<P>Comment: 18 patients were treated but no outcome data for them materialised. As a result, they are deemed as loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:04:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Quote:"All patients randomised to treatment on an intention to treat data set&#8221;</P>
<P>Comment: all patients randomised were accounted for in the statistical analysis. No evidence of loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:05:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Quote: &#8220;Two patients were diagnosed with SCC after fundus biopsies&#8230;Those patients were eliminated from the study. Histological analysis revealed lesions described as chronic inflammation.&#8221;</P>
<P>Comment: 2 patients eliminated from the study but the circumstances of exclusion adequately addressed and outcome data incorporated into the data set (n = 71). The loss to follow-up is less than 5%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:05:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Quote: &#8220;six patients were withdrawn from the study and did not complete treatment. 3 due to adverse effects, 2 non compliant, one withdrew"</P>
<P>Comment: 6 withdrawals &#8211; all accounted for in the final analysis therefore ITT performed. Losses to follow-up represent 10% of final data set.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:05:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Quote: "two patients in each group were excluded as the end stage of healing produced multiple small wounds not allowing analysis with this method"</P>
<P>Comment: 4 patients excluded which comprises 12% of the total sample. Assumed to be low risk due to small proportion of the total.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:05:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Quote: &#8220;All ulcers were evaluated weekly during the first 4 weeks and followed thereafter for up to 12 weeks&#8230;&#8221;</P>
<P>Comment: all participants were followed up. No evidence of loss to follow-up. All 15 participants accounted for in the final statistical analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:06:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Comment: all randomised patients accounted for in the final analysis. ITT assumed to be used. N = 50</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:06:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Quote: &#8220;All patients were followed up weekly to 12 weeks&#8230;&#8221;</P>
<P>Comment: all randomised patients&#8217; data included in final statistical analysis. N = 18. Therefore an ITT is assumed to be used. No evidence of loss to follow-up or withdrawals/drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:06:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Comment: all participants accounted for in the final analysis. No evidence of loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:06:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Comment: all randomised patients were accounted for in the final analysis. It is therefore assumed that an ITT was used. No evidence of loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:07:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Quote: &#8220;At unbinding of a 6-weeks run in period&#8230;.patients dropped out of the study. Thus 77 were available for analysis&#8221;</P>
<P>Comment: no evidence that dropouts were accounted for in final analysis. Loss to follow-up greater than 10%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:07:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Quote: &#8220;&#8230;15 dropped out prior to treatment. Eight patients in the mesh group dropped out because they refused to undergo the surgical procedure. Therefore the analyses was done on the 77 patients who received the treatment"</P>
<P>Comment: statistical analysis was completed on all the treated patients but there were 23 patients (15 + 8) which were randomised that were not accounted for in the final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:07:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Quote: &#8220;After completion of the therapy, 25 patients with 29 healed ulcers were followed up for 6 months&#8221;</P>
<P>Comment: it appears only patients with healed ulcers were followed up. 9 patients (9 ulcers) dropped out and a further 9 did not heal at week 12. This means that 18 ulcers were not followed up.  Losses to follow-up amounted to 19.1% and deemed unacceptable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-01 16:07:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Quote: &#8220;During follow up, 4 patients dropped out &#8221;</P>
<P>Comment: patients lost to follow-up were not accounted for in the analysis and final data set. LTF represents 10% of data and as a result, deemed at low risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-11-01 16:07:49 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Comment: no data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Comment: all primary outcomes reported (healing rate and pain)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Comment: all primary outcomes reported (wound healing at 6 months)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Comment: all primary outcomes reported (complete closure at 12 weeks, reduction in ulcer size, wound healing rate)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Comment: all primary outcomes reported (speed of epithelialisation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Comment: all primary outcomes reported (number of ulcers healed, duration of ulceration, ulcer area)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Comment: all primary outcomes reported adequately (wound healing as percentage of initial wound area)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Comment: all primary outcomes reported adequately (complete wound healing, mean reduction in initial wound area)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Comment: all outcomes reported (mean healing time, ulcer size, relief of pain)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Comment: all primary outcomes reported adequately (healing rate, peri-ulcer skin blood flow)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:38:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Comment: all outcomes adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Comment: all outcomes addressed in results equally</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Comment: all primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:39:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Comment: all outcomes reported adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-19 19:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Comment: all outcomes reported adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Comments: all outcomes addressed in results equally</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-11-01 16:07:49 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Comment: no data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:03:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Comment: it appears that the groups were balanced in baseline variables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Quote: &#8220;no significant differences between control and HSE groups in demographics at baseline&#8221;</P>
<P>Comment: it appears that the groups were comparable in terms of variables at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Quote: &#8220;the demographic limb and reference ulcer characteristics at baseline were similar across treatment group&#8221;</P>
<P>Comment: it appears that the groups were balanced in baseline variables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Comment: although the groups were comparable in age (62 vs 69 years), the mean ulcer area at baseline was 236 cm² (surgery) vs 182.3cm² (conservative), it is unclear what impact, if any, this can have on the data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Quote: &#8220;patients were reasonably well matched at randomisation with respect to baseline clinical and demographic characteristics&#8221;</P>
<P>Comment: it appears that the groups were comparable in terms of variables at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Comment: all variables balanced except mean initial wound area (4.4 cm² vs 7.9 cm²). It is unclear what impact, if any, this can have on the data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:05:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Quote: &#8220;There were no significant differences between the treatment groups in patient demographics and baseline ulcer size&#8221;</P>
<P>Comment: it appears that the groups were comparable in terms of variables at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Comment: size of ulcer prior to grafting comparable in both groups (my interpretation of table 6)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Quote: &#8220;The patients were well matched at randomisation with respect to demographics and mean ulcer duration&#8221;</P>
<P>Comment: the groups appear balanced in terms of variables at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Quote: &#8220;The ulcers had an average diameter greater than 5cm but did not extend to the fascia"</P>
<P>Comment: no evidence of comparison of baseline variables in text or figures. Unable to ascertain the demographics of the sample.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:06:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Quote: &#8220;The treatment groups were closely comparable&#8221;</P>
<P>Comment: it appears that the groups were balanced in baseline variables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Comment: not clear if variables were balanced at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Quote: &#8220;There were no significant differences between the treatment groups in the demographic CEAP classification"</P>
<P>Comment: the demographics and variables appear comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Quote: &#8220;The two treatment groups showed similar characteristics, except a nearly significant difference between the initial ulcer sizes&#8221;</P>
<P>Comment: there appear to be similarities in characteristics at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-01 16:07:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Quote: &#8220;no statistical significant differences of the variables between the 3 groups&#8221;</P>
<P>Comment: it appears that the groups were balanced in baseline variables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-11-07 13:59:32 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:03:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:03:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:04:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Quote: &#8220;The ulcers were randomly allocated to receive the allograft or placebo in a double blind fashion&#8221;</P>
<P>Comment: double-blinding referred to and assumed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:04:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Quote: &#8220;In the HSE group, the HSE was applied directly to the ulcer&#8221;</P>
<P>Comment: since the control was compression alone, it is judged to be highly likely that patients were not blinded to the addition of HSE as it was not made clear that the control looked identical to the HSE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:04:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Quote: &#8220;Double blind&#8221;</P>
<P>Comment: the study reported the study as double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:05:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Quote: "The patients were introduced to the study and the treatment (conservative or surgery)"</P>
<P>Comment: patients aware which group they were allocated to therefore blinding likely not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-07 13:59:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Quote: &#8220;Blinding not possible in the study because the characteristics of the dermagraft preclude the use of a placebo&#8221;</P>
<P>Comment: blinding not possible to the nature of the dermagraft</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:05:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:05:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Quote: &#8220;&#8230;in the Bio &#8211; MCCS group&#8230;GMB was administered using a pipette&#8221;. &#8220;in the CP group, the autologous graft was placed directly onto the wound&#8221;</P>
<P>Comment: different methods of administering the materials therefore participant blinding likely not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:06:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Quote: &#8220;sheets of Keratinocytes (cryopreserved or lyophilised) were applied on the wound bed&#8221;</P>
<P>Comment: no comment as to difference in physical appearance of the dressings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:06:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Quote: &#8220;Patients randomised to the Dermagraft group received Dermagraft at weeks 0, 1, 4 and 8 weeks&#8230;Control patients were treated with a local non-adherent dressing (Dermanet)&#8221;</P>
<P>Comment: no mention whether the Dermanet and Dermagraft were distinguishable. As a result it cannot be ascertained whether the participants can distinguish between the dressings.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:06:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Quote: &#8220;This open-label, randomised pilot study&#8230;&#8221;</P>
<P>Comment: open labelled study is therefore unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:06:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:07:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:07:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Quote: "Treatment allocation was blinded to patients and investigators until 1 week prior to the treatment"</P>
<P>Comment: it is unclear whether participants were blind at the time of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:07:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Quote: &#8220;Ulcers treated with HCD were prepared in a similar fashion (to the CCA group)&#8221;</P>
<P>Comment: although the method of preparation of ulcers is said to be "similar", it is still unclear as to the difference in appearance of the graft and dressing. Therefore, blinding is uncertain.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-01 16:07:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Quote: &#8220;all patients treated with compression bandage, patients in groups A and C were treated with hydrocolloid wound dressing"</P>
<P>Comment: different dressing used in graft group (unclear whether distinguishable from original)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-11-01 16:07:52 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:03:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown_x002d_Etris-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:03:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burdge-2000">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:04:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duhra-1992">
<DESCRIPTION>
<P>Quote: &#8220;the ulcers were examined by the same observer at 2wkly intervals&#8221;</P>
<P>Comment: judged observer to be likely blinded as dressings were of identical appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:04:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falanga-1998">
<DESCRIPTION>
<P>Comment: it is unclear whether the outcome assessor can see dressings at time of measuring the outcome. There is not enough evidence to suggest risk either way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:04:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goedkoop-2010">
<DESCRIPTION>
<P>Quote: &#8220;Blinded data&#8221;</P>
<P>Comment: the outcome assessor measured complete ulcer closure. Blinded data referred to and assumption made that the outcomes were assessed via blind fashion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:05:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jankunas-2007">
<DESCRIPTION>
<P>Comment: not clear whether outcome assessor can distinguish between intervention and control. Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:05:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krishnamoorthy-2003">
<DESCRIPTION>
<P>Quote: &#8220;Open-label, prospective, multi centre, randomised, controlled clinical trial"</P>
<P>Comment: open label. Blinding not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:05:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindgren-1998">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:05:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Quote: &#8220;The wound surface was were calculated using computerised image analysis"</P>
<P>Comment: assessors were judged to be blind as calculations were made remotely using a computerised system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:06:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navratilova-2004">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:06:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Omar-2004">
<DESCRIPTION>
<P>Quote: "ulcer measurements were made by a clinician blinded to the treatment group"</P>
<P>Comment: the outcome assessors are said to be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:06:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Paquet-2005">
<DESCRIPTION>
<P>Quote: &#8220;these measurements were made by one single-blind investigator&#8221;</P>
<P>Comment: outcome assessor blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:06:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poskitt-1987">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:07:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salomon-2002">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:07:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tausche-2003">
<DESCRIPTION>
<P>Comment: not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:07:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teepe-1993">
<DESCRIPTION>
<P>Quote: &#8220;Ulcers treated with HCD were prepared in a similar fashion (to the CCA group)&#8221;</P>
<P>Comment: although the method of preparation of ulcers is said to be "similar", it is still unclear as to the difference in appearance of the graft and dressing. Therefore, blinding of the outcome assessor is uncertain.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-01 16:07:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Warburg-1994">
<DESCRIPTION>
<P>Quote: &#8220;all patients treated with compression bandage, patients in groups A and C were treated with hydrocolloid wound dressing"</P>
<P>Comment: different dressing used in graft group (unclear whether distinguishable from original)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-11-01 16:08:48 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-11-01 16:08:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Quality appraisal</TITLE>
<TABLE COLS="10" ROWS="18">
<TR>
<TH VALIGN="BOTTOM">
<P>STUDY REF</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Intention-to-treat</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Blind outcome assessment</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Groups comparable</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Similar care</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Clear entry criteria</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Ulcer aetiology clear</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Adverse events</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Sample size OK</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Follow-up %</P>
</TH>
</TR>
<TR>
<TD>
<P>Brown-<BR/>Etris</P>
</TD>
<TD>
<P>No W/D reported</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Area similar at baseline</P>
</TD>
<TD>
<P>Both received foam and compression</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Criteria N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>No information on withdrawals</P>
</TD>
</TR>
<TR>
<TD>
<P>Burdge</P>
</TD>
<TD>
<P>No W/D reported</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Patient age and ulcer duration comparable. No information on area of ulcer.</P>
</TD>
<TD>
<P>Both received debridement and compression</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Definition of venous ulcers by duplex</P>
</TD>
<TD>
<P>'No infections'</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
</TR>
<TR>
<TD>
<P>Duhra</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Comparable for area and duration</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Reported by group and type</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Falanga</P>
</TD>
<TD>
<P>No: 309 randomised, 293 treated, data on 275</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Comparable for area and duration</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Reported by group and type</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>89%</P>
</TD>
</TR>
<TR>
<TD>
<P/>
<P>Goedkoop</P>
</TD>
<TD>
<P>No: 110 (randomised)</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Comparable for area and duration</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Jankunas</P>
</TD>
<TD>
<P>No: 71 randomised</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Larger and older ulcers in graft group</P>
</TD>
<TD>
<P>Both received compression</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Squamous cell carcinoma</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
</TR>
<TR>
<TD>
<P>Krishnamoorthy</P>
</TD>
<TD>
<P>No: 53 randomised, 52 analysed</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Ulcer duration longer in control group</P>
</TD>
<TD>
<P>Both received compression</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Infections, skin problems</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>98%</P>
</TD>
</TR>
<TR>
<TD>
<P>Lindgren</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Larger and older ulcers in graft group</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Types of adverse events reported but no numbers</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Older but smaller ulcers in microbead group</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Definition of venous ulcers by both continuous wave Doppler and Duplex ultrasound</P>
</TD>
<TD>
<P>No "contact dermatitis or infection throughout entire treatment period"</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Navratilova</P>
</TD>
<TD>
<P>No W/D reported</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Longer duration and larger ulcers in frozen graft group</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Omar</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Comparable for ulcer duration and area</P>
</TD>
<TD>
<P>Dressing and compression</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Paquet</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Comparable</P>
</TD>
<TD>
<P>Dressing and compression</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Poskitt</P>
</TD>
<TD>
<P>Unclear: 51 people (60 legs) 'entered study' but data on 53 'available for randomisation'</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Larger and older ulcers in graft group</P>
</TD>
<TD>
<P>Both received compression</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Stated they needed 40 per group</P>
</TD>
<TD>
<P>88%</P>
</TD>
</TR>
<TR>
<TD>
<P>Salomon</P>
</TD>
<TD>
<P>92 randomised, data on 77</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S abstract only</P>
</TD>
<TD>
<P>N/S abstract only</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>N/S</P>
</TD>
</TR>
<TR>
<TD>
<P>Tausche</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Larger ulcers in graft group</P>
</TD>
<TD>
<P>Compression therapy</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>Teepe</P>
</TD>
<TD>
<P>Yes - but unit of analysis error</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Larger ulcers in graft group</P>
</TD>
<TD>
<P>Both received tulle and compression</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Definition of venous ulcer by clinical findings/LRR/Doppler</P>
</TD>
<TD>
<P>"Side effects not observed"</P>
</TD>
<TD>
<P>Stated they needed 20 per group</P>
</TD>
<TD>
<P>81%</P>
</TD>
</TR>
<TR>
<TD>
<P>Warburg</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>Ulcer areas not similar at baseline (7 vs 41 cm²)</P>
</TD>
<TD>
<P>Both received surgery to incompetent perforators</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Definition of venous ulcers by phlebography</P>
</TD>
<TD>
<P>"No thrombosis or sepsis"</P>
</TD>
<TD>
<P>N/S</P>
</TD>
<TD>
<P>90%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>LRR = light reflection rheography<BR/>N/S = not stated<BR/>W/D = withdrawal<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-11-07 13:53:02 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-08-19 08:48:14 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Split-thickness autografts compared with standard care</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-08-19 08:48:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Healing</NAME>
<GROUP_LABEL_1>Autograft</GROUP_LABEL_1>
<GROUP_LABEL_2>Dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dressing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours autograft</GRAPH_LABEL_2>
<DICH_DATA CI_END="677.1647290373737" CI_START="2.72121773626436" EFFECT_SIZE="42.926829268292686" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" LOG_CI_END="2.830694329260641" LOG_CI_START="0.43476329292818827" LOG_EFFECT_SIZE="1.6327288110944143" MODIFIED="2009-08-18 17:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.4073817507915887" STUDY_ID="STD-Jankunas-2007" TOTAL_1="40" TOTAL_2="31" VAR="1.980723392461197" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.310318187075823" CI_START="0.34199767859256874" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3636717969375798" LOG_CI_START="-0.4659768418323424" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="24311" O_E="0.0" SE="0.4873397172404482" STUDY_ID="STD-Warburg-1994" TOTAL_1="15" TOTAL_2="16" VAR="0.23750000000000004" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-11-07 13:53:02 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Frozen or fresh allografts compared with standard care</NAME>
<DICH_OUTCOME CHI2="1.6454396366326378" CI_END="3.839813786420528" CI_START="1.040629196011293" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.998955310504933" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.5843101635625986" LOG_CI_START="0.017296006346415444" LOG_EFFECT_SIZE="0.30080308495450697" METHOD="MH" MODIFIED="2012-11-07 13:53:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6491311972332632" P_Q="0.3374773047569656" P_Z="0.037568100597839445" Q="0.919991651769482" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="58" WEIGHT="99.99999999999999" Z="2.07953612955239">
<NAME>Healing</NAME>
<GROUP_LABEL_1>Skin graft</GROUP_LABEL_1>
<GROUP_LABEL_2>Dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dressing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours graft</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7573377328441466" CI_END="3.3259346683322284" CI_START="0.7885640130404901" DF="1" EFFECT_SIZE="1.6194790486976216" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.5219137140772847" LOG_CI_START="-0.10316304630229833" LOG_EFFECT_SIZE="0.2093753338874932" NO="1" P_CHI2="0.38416299366338225" P_Z="0.1891773197459509" STUDIES="3" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="81.9965177016831" Z="1.3130167034888194">
<NAME>Frozen allografts</NAME>
<DICH_DATA CI_END="4.873702707246154" CI_START="0.1313169962231092" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6878590339705114" LOG_CI_START="-0.881679059986624" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="24312" O_E="0.0" SE="0.9219544457292888" STUDY_ID="STD-Lindgren-1998" TOTAL_1="15" TOTAL_2="12" VAR="0.85" WEIGHT="21.82240278583865"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24313" O_E="0.0" SE="0.0" STUDY_ID="STD-Paquet-2005" TOTAL_1="3" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.2477056014095735" CI_START="0.8648459794134622" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.628154409176546" LOG_CI_START="-0.0630612292366097" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="24314" O_E="0.0" SE="0.40602348757648016" STUDY_ID="STD-Teepe-1993" TOTAL_1="24" TOTAL_2="23" VAR="0.16485507246376813" WEIGHT="60.17411491584445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.024582491357144128" CI_END="17.453140301075063" CI_START="0.7959921105209549" DF="1" EFFECT_SIZE="3.727272727272727" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.241873579875546" LOG_CI_START="-0.09909123675252507" LOG_EFFECT_SIZE="0.5713911715615104" NO="2" P_CHI2="0.8754119117983109" P_Z="0.09486021468148102" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="20" WEIGHT="18.003482298316886" Z="1.6702990316491266">
<NAME>Fresh allografts</NAME>
<DICH_DATA CI_END="23.72477964719028" CI_START="0.67440036274035" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.3752021874447993" LOG_CI_START="-0.1710822047888746" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="24315" O_E="0.0" SE="0.9082951062292475" STUDY_ID="STD-Burdge-2000" TOTAL_1="10" TOTAL_2="5" VAR="0.825" WEIGHT="13.09344167150319"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="24316" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Duhra-1992" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="4.9100406268136965"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-06 16:00:49 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Bilayered human skin equivalent compared with standard care</NAME>
<DICH_OUTCOME CHI2="0.5467536263632358" CI_END="1.8794181559214909" CI_START="1.2168898062775553" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.512297852829866" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2740234179957752" LOG_CI_START="0.08525125309257735" LOG_EFFECT_SIZE="0.17963733554417627" METHOD="MH" MODIFIED="2009-11-06 16:00:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4596472949965672" P_Q="1.0" P_Z="1.912977206435518E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="171" TOTAL_2="174" WEIGHT="100.0" Z="3.7302396582236588">
<NAME>Healing</NAME>
<GROUP_LABEL_1>Skin replacement</GROUP_LABEL_1>
<GROUP_LABEL_2>Dressing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dressing</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours skin graft</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5467536263632358" CI_END="1.8794181559214909" CI_START="1.2168898062775553" DF="1" EFFECT_SIZE="1.512297852829866" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="70" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.2740234179957752" LOG_CI_START="0.08525125309257735" LOG_EFFECT_SIZE="0.17963733554417627" NO="1" P_CHI2="0.4596472949965672" P_Z="1.912977206435518E-4" STUDIES="2" TAU2="0.0" TOTAL_1="171" TOTAL_2="174" WEIGHT="100.0" Z="3.7302396582236588">
<NAME>Bilayer skin replacement</NAME>
<DICH_DATA CI_END="3.7214489078723574" CI_START="0.9864241818936951" EFFECT_SIZE="1.915966386554622" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5707120608983806" LOG_CI_START="-0.005936289682534399" LOG_EFFECT_SIZE="0.28238788560792305" ORDER="24317" O_E="0.0" SE="0.33872609558660083" STUDY_ID="STD-Brown_x002d_Etris-2000" TOTAL_1="17" TOTAL_2="19" VAR="0.11473536783134303" WEIGHT="9.525104716313985"/>
<DICH_DATA CI_END="1.8503019182172769" CI_START="1.1675457610058808" EFFECT_SIZE="1.4698000412286127" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="63" LOG_CI_END="0.26724259906110515" LOG_CI_START="0.06727391139049882" LOG_EFFECT_SIZE="0.167258255225802" ORDER="24318" O_E="0.0" SE="0.11746259699868242" STUDY_ID="STD-Falanga-1998" TOTAL_1="154" TOTAL_2="155" VAR="0.013797461693674875" WEIGHT="90.47489528368601"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-10-29 14:12:39 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Single-layered dermal skin replacement compared with standard care</NAME>
<DICH_OUTCOME CHI2="2.2169933827822073" CI_END="4.771635803691093" CI_START="0.9636424270295774" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1443298969072164" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" I2="0.0" I2_Q="5.524137546173537" ID="CMP-004.01" LOG_CI_END="0.6786672886271271" LOG_CI_START="-0.01608408723409374" LOG_EFFECT_SIZE="0.3312916006965167" METHOD="MH" NO="1" P_CHI2="0.5286090560323302" P_Q="0.3469859883583145" P_Z="0.061593004589956604" Q="2.1169428339195817" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="47" WEIGHT="300.0" Z="1.8692143068904161">
<NAME>Healing</NAME>
<GROUP_LABEL_1>Single layer graft</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Standard care better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dermal graft better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.641353375992068" CI_START="0.5873313082620311" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="1.0269968653977113" LOG_CI_START="-0.23111684805363597" LOG_EFFECT_SIZE="0.3979400086720376" NO="1" P_CHI2="1.0" P_Z="0.21502388181975396" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.239868982693371">
<NAME>Twelve pieces of Dermagraft</NAME>
<DICH_DATA CI_END="10.641353375992068" CI_START="0.5873313082620311" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0269968653977113" LOG_CI_START="-0.23111684805363597" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="24319" O_E="0.0" SE="0.739022223044643" STUDY_ID="STD-Krishnamoorthy-2003" TOTAL_1="13" TOTAL_2="13" VAR="0.5461538461538462" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14706484777881407" CI_END="9.675033409018543" CI_START="0.9525094989232334" DF="1" EFFECT_SIZE="3.0357142857142856" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.9856524733630263" LOG_CI_START="-0.021130684618879295" LOG_EFFECT_SIZE="0.4822608943720735" NO="2" P_CHI2="0.7013563673334533" P_Z="0.060423408726865566" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="21" WEIGHT="99.99999999999999" Z="1.8776912915707062">
<NAME>Four pieces of Dermagraft</NAME>
<DICH_DATA CI_END="10.641353375992068" CI_START="0.5873313082620311" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0269968653977113" LOG_CI_START="-0.23111684805363597" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="24320" O_E="0.0" SE="0.739022223044643" STUDY_ID="STD-Krishnamoorthy-2003" TOTAL_1="13" TOTAL_2="13" VAR="0.5461538461538462" WEIGHT="64.28571428571428"/>
<DICH_DATA CI_END="27.704745859881754" CI_START="0.5775183819018179" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.4425541706606146" LOG_CI_START="-0.23843418800468977" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="24321" O_E="0.0" SE="0.9874208829065749" STUDY_ID="STD-Omar-2004" TOTAL_1="10" TOTAL_2="8" VAR="0.9749999999999999" WEIGHT="35.71428571428571"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.533104662549071" CI_START="0.04755266876379176" DF="0" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.6563957463789577" LOG_CI_START="-1.3228251044497223" LOG_EFFECT_SIZE="-0.33321467903538243" NO="3" P_CHI2="1.0" P_Z="0.5092889230575157" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.6599453211661364">
<NAME>One piece of Dermagraft</NAME>
<DICH_DATA CI_END="4.533104662549071" CI_START="0.04755266876379176" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6563957463789577" LOG_CI_START="-1.3228251044497223" LOG_EFFECT_SIZE="-0.33321467903538243" ORDER="24322" O_E="0.0" SE="1.162604125077987" STUDY_ID="STD-Krishnamoorthy-2003" TOTAL_1="14" TOTAL_2="13" VAR="1.3516483516483517" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-07-22 11:09:19 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Allogenic tissue product compared with placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="71" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-07-14 16:20:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="132" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Complete wound closure</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="3" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-07-14 16:18:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="3.176444884478343" CI_START="0.49389161948927995" EFFECT_SIZE="1.2525252525252526" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" LOG_CI_END="0.5019413241527585" LOG_CI_START="-0.3063683430233882" LOG_EFFECT_SIZE="0.09778649056468518" MODIFIED="2011-07-14 16:17:06 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.4748050996966516" STUDY_ID="STD-Goedkoop-2010" TOTAL_1="66" TOTAL_2="8" VAR="0.22543988269794724" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="4" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-07-14 16:20:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="2.489556080114035" CI_START="0.5901605690308039" EFFECT_SIZE="1.2121212121212122" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="4" LOG_CI_END="0.3961219137043694" LOG_CI_START="-0.22902981080421958" LOG_EFFECT_SIZE="0.08354605145007492" MODIFIED="2011-07-14 16:20:22 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.3672172175272898" STUDY_ID="STD-Goedkoop-2010" TOTAL_1="66" TOTAL_2="8" VAR="0.13484848484848488" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-09-19 19:43:19 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Autograft versus comparator graft</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-19 19:43:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Proportion fully healed in trial</NAME>
<GROUP_LABEL_1>Autograft</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator graft</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours comparison graft</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours autograft</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-08-18 17:08:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Autograft versus frozen allograft</NAME>
<DICH_DATA CI_END="2.283697545426482" CI_START="0.38641762134278784" EFFECT_SIZE="0.9393939393939394" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.3586385851034713" LOG_CI_START="-0.4129430771907009" LOG_EFFECT_SIZE="-0.027152246043614773" MODIFIED="2009-08-18 17:08:52 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.45323088782242343" STUDY_ID="STD-Tausche-2003" TOTAL_1="45" TOTAL_2="47" VAR="0.20541823767630218" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-19 19:43:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Autograft versus xenograft</NAME>
<DICH_DATA CI_END="1.0603972398430932" CI_START="0.10712397209890277" EFFECT_SIZE="0.337037037037037" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.025468588617379925" LOG_CI_START="-0.9701133322931675" LOG_EFFECT_SIZE="-0.4723223718378937" MODIFIED="2009-08-18 17:09:34 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.5848097485528452" STUDY_ID="STD-Poskitt-1987" TOTAL_1="25" TOTAL_2="28" VAR="0.342002442002442" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2009-11-06 15:46:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="47" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in ulcer area</NAME>
<GROUP_LABEL_1>Autograft</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator graft</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.01" MODIFIED="2009-08-18 17:21:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Autograft versus frozen allograft</NAME>
<CONT_DATA CI_END="42.50013979017572" CI_START="-13.760139790175714" EFFECT_SIZE="14.370000000000005" ESTIMABLE="YES" MEAN_1="65.87" MEAN_2="51.5" MODIFIED="2009-08-18 17:21:05 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="63.04" SD_2="74.37" SE="14.352375866119312" STUDY_ID="STD-Tausche-2003" TOTAL_1="45" TOTAL_2="47" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-07-22 11:09:14 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Autograft on microbeads compared with autograft on pads</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.931478136347037" CI_START="0.08381191236932206" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.0">
<NAME>Healing</NAME>
<GROUP_LABEL_1>Autograft on beads</GROUP_LABEL_1>
<GROUP_LABEL_2>Autograft on pads</GROUP_LABEL_2>
<GRAPH_LABEL_1>Pad delivery better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Bead delivery better</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.931478136347037" CI_START="0.08381191236932206" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0766942497636753" LOG_CI_START="-1.0766942497636753" LOG_EFFECT_SIZE="0.0" ORDER="24327" O_E="0.0" SE="1.2649110640673518" STUDY_ID="STD-Liu-2004" TOTAL_1="5" TOTAL_2="5" VAR="1.6" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-07-22 11:09:11 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Autograft versus cultured autologous keratinocytes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9372867443545452" CI_START="0.563088660318229" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0444444444444445" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.28719390687000285" LOG_CI_START="-0.24942321854925523" LOG_EFFECT_SIZE="0.018885344160373813" METHOD="MH" MODIFIED="2009-08-19 14:58:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8902757270813823" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="47" WEIGHT="100.0" Z="0.13795532284236015">
<NAME>Number of ulcers healed at 12 weeks</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9372867443545452" CI_START="0.563088660318229" EFFECT_SIZE="1.0444444444444445" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.28719390687000285" LOG_CI_START="-0.24942321854925523" LOG_EFFECT_SIZE="0.018885344160373813" MODIFIED="2009-08-19 14:58:29 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.3152115557688832" STUDY_ID="STD-Salomon-2002" TOTAL_1="45" TOTAL_2="47" VAR="0.09935832489023977" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-07-22 11:09:06 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Frozen allograft compared with lyophilised keratinocyte</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.361993498747681" CI_START="0.8094752295174106" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.13417503454831828" LOG_CI_START="-0.0917964364084421" LOG_EFFECT_SIZE="0.021189299069938092" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.71319325313003" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.3675708518326506">
<NAME>Healing</NAME>
<GROUP_LABEL_1>Frozen allograft</GROUP_LABEL_1>
<GROUP_LABEL_2>Lyophilised Keratino</GROUP_LABEL_2>
<GRAPH_LABEL_1>Keratinocytes better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Allografts better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.361993498747681" CI_START="0.8094752295174107" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.13417503454831828" LOG_CI_START="-0.09179643640844204" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="24328" O_E="0.0" SE="0.1327367606168224" STUDY_ID="STD-Navratilova-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.017619047619047618" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-11-07 13:59:33 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-11-07 13:59:33 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-11-07 13:58:13 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-11-07 13:58:13 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-10-28 12:26:10 +0100" MODIFIED_BY="[Empty name]">Search strategy - third update 2009</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-07 13:58:13 +0000" MODIFIED_BY="[Empty name]">
<P>For this third update we searched the following electronic databases:</P>
<UL>
<LI>Cochrane Wounds Group Specialised Register (Searched 22/5/09)</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library Issue 2 2009</LI>
<LI>Ovid MEDLINE - 1950 to May Week 2 2009</LI>
<LI>Ovid EMBASE - 1980 to 2009 Week 20</LI>
<LI>Ovid CINAHL - 1982 to May Week 3 2009</LI>
</UL>
<P>The following search strategy was used in The Cochrane Central Register of Controlled Trials (CENTRAL):</P>
<P>#1 MeSH descriptor Leg Ulcer explode all trees<BR/>#2 (varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg NEXT ulcer*) or (foot NEXT ulcer*) or (stasis NEXT ulcer*) or ((lower NEXT extremit*) NEAR/2 ulcer*) or (crural NEXT ulcer*) or &#8220;ulcus cruris&#8221;:ti,ab,kw<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Skin Transplantation explode all trees<BR/>#5 (skin NEXT graft*) or (pinch NEXT graft*):ti,ab,kw<BR/>#6 (split NEXT thickness) or (full NEXT thickness):ti,ab,kw<BR/>#7 allograft* or dermagraft* or apligraf*:ti,ab,kw<BR/>#8 tissue NEAR/2 engineer*:ti,ab,kw<BR/>#9 cultured NEAR/2 keratinocyte*:ti,ab,kw<BR/>#10 artificial NEXT skin:ti,ab,kw<BR/>#11 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)<BR/>#12 (#3 AND #11)</P>
<P>The search strategies for Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>, <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> and Appendix 6 respectively. The Ovid MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision); Ovid format. The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN). No date or language restrictions were applied.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-10-28 12:26:21 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-08-21 12:21:24 +0100" MODIFIED_BY="[Empty name]">Ovid MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-21 12:28:32 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp Leg Ulcer/<BR/>2 (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet adj ulcer*) or stasis ulcer* or (lower extremit* adj ulcer*) or crural ulcer* or ulcus cruris).ti,ab.<BR/>3 or/1-2<BR/>4 exp Skin Transplantation/<BR/>5 (skin graft$ or pinch graft$).ti,ab.<BR/>6 (split thickness or full thickness).ti,ab.<BR/>7 (allograft$ or dermagraft$ or apligraf$).ti,ab.<BR/>8 (tissue adj2 engineer$).ti,ab.<BR/>9 (cultured adj2 keratinocyte$).ti,ab.<BR/>10 artificial skin.ti,ab.<BR/>11 or/4-10<BR/>12 3 and 11<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-10-28 12:26:26 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-08-21 12:21:36 +0100" MODIFIED_BY="[Empty name]">Ovid EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-21 12:28:03 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp Leg Ulcer/ <BR/>2 (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet adj ulcer*) or stasis ulcer* or (lower extremit* adj ulcer*) or crural ulcer* or ulcus cruris).ti,ab. <BR/>3 or/1-2 <BR/>4 exp Skin Graft/ <BR/>5 (skin graft* or pinch graft*).ti,ab. <BR/>6 (split thickness or full thickness).ti,ab. <BR/>7 (allograft* or dermagraft* or apligraf*).ti,ab. <BR/>8 exp Tissue Engineering/ <BR/>9 (tissue adj2 engineer*).ti,ab. <BR/>10 (cultured adj2 keratinocyte*).ti,ab. <BR/>11 exp Artificial Skin/ <BR/>12 artificial skin.ti,ab. <BR/>13 or/4-12 <BR/>14 3 and 13</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-10-28 12:26:32 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-08-21 12:21:52 +0100" MODIFIED_BY="[Empty name]">EBSCO CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-21 12:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>S13 S4 and S12<BR/>S12 S5 or S6 or S7 or S8 or S9 or S10 or S11<BR/>S11 TI artificial skin or AB artificial skin<BR/>S10 TI cultured N2 keratinocyte* or AB cultured N2 keratinocyte*<BR/>S9 TI tissue N2 engineer* or AB tissue N2 engineer*<BR/>S8 TI ( allograft* or dermagraft* or apligraf* ) or AB ( allograft* or dermagraft* or apligraf* )<BR/>S7 TI ( split thickness or full thickness ) or AB ( split thickness or full thickness )<BR/>S6 TI ( skin graft* or pinch graft* ) or AB ( skin graft* or pinch graft* )<BR/>S5 (MH "Skin Transplantation")<BR/>S4 S1 or S2 or S3<BR/>S3 lower extremity N3 ulcer* or AB lower extremity N3 ulcer*<BR/>S2 TI (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet N1 ulcer*) or stasis ulcer* or crural ulcer*) or AB (varicose ulcer* or venous ulcer* or leg ulcer* or foot ulcer* or (feet N1 ulcer*) or stasis ulcer* or crural ulcer*)<BR/>S1 (MH "Leg Ulcer+")<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-11-01 16:17:13 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-11-01 16:16:55 +0000" MODIFIED_BY="[Empty name]">Risk of Bias definitions</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-01 16:17:13 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1.  Was the allocation sequence randomly generated?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Low risk of bias</HEADING>
<P>The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">High risk of bias</HEADING>
<P>The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.  Was the treatment allocation adequately concealed?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Low risk of bias</HEADING>
<P>Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation); sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">High risk of bias</HEADING>
<P>Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.  Blinding - was knowledge of the allocated interventions adequately prevented during the study?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Low risk of bias</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.</LI>
<LI>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</LI>
<LI>Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">High risk of bias</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.</LI>
<LI>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.</LI>
<LI>Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>Insufficient information to permit judgement of low or high risk of bias.</LI>
<LI>The study did not address this outcome.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Were incomplete outcome data adequately addressed?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Low risk of bias</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>No missing outcome data.</LI>
<LI>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).</LI>
<LI>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</LI>
<LI>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.</LI>
<LI>For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size.</LI>
<LI>Missing data have been imputed using appropriate methods.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">High risk of bias</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.</LI>
<LI>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate.</LI>
<LI>For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size.</LI>
<LI>&#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation.</LI>
<LI>Potentially inappropriate application of simple imputation.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).</LI>
<LI>The study did not address this outcome.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Are reports of the study free of suggestion of selective outcome reporting?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Low risk of bias</HEADING>
<P>Any of the following.</P>
<UL>
<LI>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.</LI>
<LI>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">High risk of bias</HEADING>
<P>Any one of the following.</P>
<UL>
<LI>Not all of the study&#8217;s pre-specified primary outcomes have been reported.</LI>
<LI>One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified.</LI>
<LI>One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).</LI>
<LI>One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.</LI>
<LI>The study report fails to include results for a key outcome that would be expected to have been reported for such a study.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Other sources of potential bias</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Low risk of bias</HEADING>
<P>The study appears to be free of other sources of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">High risk of bias</HEADING>
<P>There is at least one important risk of bias. For example, the study:</P>
<UL>
<LI>had a potential source of bias related to the specific study design used; or</LI>
<LI>had extreme baseline imbalance; or</LI>
<LI>has been claimed to have been fraudulent; or</LI>
<LI>had some other problem.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>There may be a risk of bias, but there is either:</P>
<UL>
<LI>insufficient information to assess whether an important risk of bias exists; or</LI>
<LI>insufficient rationale or evidence that an identified problem will introduce bias.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>